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ABSTRACT
Statistical Methods have been widely used in understanding factors for clinical and
public health data. Statistical hypotheses are procedures for testing pre-stated hy-
potheses. The development and properties of these procedures as well as their perfor-
mance are based upon certain assumptions. Desirable properties of statistical tests
are to maintain validity and to perform well even if these assumptions are not met. A
statistical test that maintains such desirable properties is called robust. Mathemati-
cal models are typically mechanistic framework, used to study dynamic interactions
between components (mechanisms) of a system, and how these interactions give rise
to the changes in behavior (patterns) of the system as a whole over time. In this
thesis, I have developed a study that uses novel techniques to link robust statistical
tests and mathematical modeling methods guided by limited data from developed and
developing regions in order to address pressing clinical and epidemiological questions
of interest. The procedure in this study consists of three primary steps, namely, data
collection, uncertainty quantification in data, and linking dynamic model to collected
data. The first part of the study focuses on designing, collecting, and summarizing
empirical data from the only national survey of hospitals ever conducted regarding
patient controlled analgesia (PCA) practices among 168 hospitals across 40 states,
in order to assess risks before putting patients on PCA. I used statistical relational
models and exploratory data analysis to address the question. Risk factors assessed
indicate a great concern for the safety of patients from one healthcare institution
to other. In the second part, I quantify uncertainty associated with data obtained
from James A Lovell Federal Healthcare Center to primarily study the effect of Be-
nign Prostatic Hypertrophy (BPH) on sleep architecture in patients with Obstructive
Sleep Apnea (OSA). Patients with OSA and BPH demonstrated significant difference
in their sleep architecture in comparison to patients without BPH. One of the ways
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to validate these differences in sleep architecture between the two groups may be to
carry out a similar study that evaluates the effect of some other chronic disease on
sleep architecture in patients with OSA. Additionally, I also address theoretical sta-
tistical questions such as (1) how to estimate the distribution of a variable in order
to retest null hypothesis when the sample size is limited, and (2) how changes on
assumptions (like monotonicity and nonlinearity) translate into the effect of the inde-
pendent variable on the outcome variable. To address these questions we use multiple
techniques such as Partial Rank Correlation Coefficients (PRCC) based sensitivity
analysis, Fractional Polynomials, and statistical relational models. In the third part,
my goal was to identify socio-economic-environment-related risk factors for Visceral
Leishmaniasis (VL) and use the identified critical factors to develop a mathematical
model to understand VL transmission dynamics when data is highly underreported.
I primarily studied the role of age-specific- susceptibility and epidemiological quanti-
ties on the dynamics of VL in the Indian state of Bihar. Statistical results provided
ideas on the choice of the modeling framework and estimates of model parameters. In
the conclusion, this study addressed three primary theoretical modeling-related ques-
tions (1) how to analyze collected data when sample size limited, and how modeling
assumptions varies results of data analysis? (2) Is it possible to identify hidden asso-
ciations and nonlinearity of these associations using such underpowered data and (3)
how statistical models provide more reasonable structure to mathematical modeling
framework that can be used in turn to understand dynamics of the system.
ii
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Chapter 1
INTRODUCTION TO CLINICAL PROBLEMS AND MATHEMATICAL
MODELS
This dissertation, Quantitative Modeling Methods For Analyzing Clinical To Pub-
lic Health Problems, focuses on the adaptation of techniques linking statistical and
mathematical modeling methods. The novelty comes from the implementation of
these methods using limited multinational clinical data. And so, the generated statis-
tical hypotheses and the statistical and mathematical methods involved in analyzing
the data, are used to quantify the degree of confidence in the existing experimental
data and parameter estimates; in other words, to assess uncertainty, a process that,
in general, demands the prior identification of as many sources of uncertainty in the
data and the model inputs. The results are collected in the first four chapters of this
dissertation. Three of them statistical in nature and a fourth assessing uncertainty
in a dynamic setting.
Statistical Methods are systematically used to help, guide, improve and/or assess,
for example, our clinical trial outcomes and public health data, often carried out via
the acceptance or rejection of statistical hypotheses. The development and imple-
mentation of project- or question-tailored statistical hypotheses procedures, involve
assessment of their performance. The process of assessing the validity of such proce-
dures is invariably tied in to pre-determined sets of assumptions and such a discussion
is the driver of Chapter one.
The applicability of statistical methodology depends, strictly speaking, on whether
or not the assumptions of the procedures are met. Today, advances in computa-
tional statistics allow for testing whether or not the methodology performs well when
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assumptions are not strictly met. A statistical test that maintains such desirable
property is called robust. Testing for statistical robustness is naturally important in
the context of nonlinear dynamics mathematical models, the kind used to study in-
teractions between components of a system and the resulting system dynamics. The
mathematical models that form part of this dissertation require input factors modeled
by parameters and system’s initial conditions linked to independent and dependent
model variables. Inputs that are not known, in general, with a sufficient degree of cer-
tainty due natural variation, errors in measurements, and/or even a lack of techniques
to measure them.
Chapter two involves the analysis of the only national survey of hospitals ever
conducted regarding patient controlled analgesia (PCA) practices among 168 hospi-
tals across 40 states, in order to assess risks before putting patients on PCA. The
challenges in collecting sufficient data include lack of financial and human resources
and difficulty in meeting ethical standards inherent to the process of data collection
via surveys. And so, Chapter two revisits challenges in designing, implementing, col-
lecting, cleaning, and summarizing available empirical data. We also used these data
to describe the processes of gathering data from surveys and their analyses using
simple statistical methods for generating relevant estimates from these data under
pre-specified statistical distributions.
We had access to James A Lovell Federal Healthcare Center limited data collected
from patients undergoing treatment. The survey’s responses were used in evaluating
the effect of Benign Prostatic Hypertrophy (BPH) on the sleep architecture of patients
diagnosed, via polysomnography, with Obstructive Sleep Apnea (OSA). Uncertainty
may come from fronts that include the collection of data by clinicians in a set up de-
signed without consulting a statistician (underpowered data). The question whether
or not we can guarantee reasonable power to detect an effect size significantly differ-
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ent than zero, if one exists, needs to be addressed and, so, it is the driving force of
Chapter 3. In this chapter, rather than generating simulated data from the survey
data with replacement, I have simulated such data from my pre-specified distributions
on the variables. The use of this approach increases precision, which allows finding
associations that were considered null when tested under the ‘typical replacement
approach. Yes, the results of this chapter identify relationships previously observed
between OSA and BPH. However, the main point here is that these simple associa-
tions were not coming to light before my proposed method. This chapter identifies
relationships between OSA and BPH using various approaches. The first determined
the distribution of each of the variables in the under sampled data and resampling
the variables assuming unique distributions in order to retest hypotheses. The second
starts from the view that typically when studying associations, the natural starting
point is to assume that the influence, the independent variable, has on the outcome
variable is monotonic. And so, a straight-line model of the form β0 + β1X would
suffice. However, the relationship will not be monotonic for all-time and so, we intro-
duce alternative models that address associations that bring possible improvements
in fit when considering non-linearity via fractional polynomials.
Chapter four focused on the Influence of Under-Reporting in identifying Risk
Factors for Kalaazar or Leishmaniasis, a vector-borne disease caused by a protozoan
parasite and transmitted by the bite of a specific species of sandflies in Bihar, India.
A problem that makes use of data collected in India, which due to the limitations
imposed by multiple levels of data collection efforts, brings additional sources of
uncertainty. It is believed that early diagnosis is now feasible with the increasing
use of field-based rapid diagnostic tests (rK39) to detect antibodies to recombinant
antigen rK39 which are highly sensitive (range 98% - 99%) and specific (range 96% -
97%) [65]. Amidst these advances, approximately one-third of physicians (especially
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in the private sector) in India still rely on tests other than rK39 (despite availability)
for VL diagnosis [41]. This continues to pose an under-reporting problem despite the
advances via active case detection strategies. Chapter four aims to identify risk factors
that are significant in predicting the true burden of Kala-azar in Bihar. And so, the
first step is to estimate the true disease burden in Bihar using reported incidence
and mortality data from 2003 to 2005. This was achieved by fitting a dynamical
mathematical model to the temporal reported incidence and mortality data via a
Bayesian parameter estimation procedure. Next, I identified and ranked risk factors
using multivariate regression models on datasets that included socio-economic and
climate factors and the true incidence and true mortality. Nonlinear models were
used to make predictions on future Kala-azar burden in Bihar by connecting ranked
risk factors and estimates of underreporting levels to compute the needed adjusted
incidence rates to assess Kala-azars future transmission dynamics in a setting where
control measures can be explored and assessed.
In conclusion, testing for statistical robustness, in the context of multiple settings
of importance to clinical and public health settings, is the underlying methodologi-
cal theme of my dissertation. The content of this dissertation collects my efforts to
introduce methods that help identify associations that often go undetected when us-
ing standard statistical procedures for assessing uncertainty the only national survey
of hospitals ever conducted regarding patient controlled analgesia (PCA) practices
among 168 hospitals across 40 states. We used nonlinear dynamics mathematical
models to estimate disease burden for Kala-azar burden in Bihar in order to improve
the forecasting on disease prevalence in a setting where it is possible to introduce
and test specific control methods. In short, this dissertation addressed three primary
theoretical modeling-related questions: (1) How do we analyze collected data when
sample size is limited and how do modeling assumptions impact the results of data
4
analysis? (2) Is it possible to identify hidden associations and quantify nonlinear as-
sociations using underpowered data? And (3) How can statistical models help inform
mathematical modeling frameworks used to understand the nonlinear dynamics of a
system?
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Chapter 2
CLINICAL AND FINANCIAL IMPLICATIONS FOR HOSPITAL PRACTICE:
RESULTS FROM FIRST NATIONAL HOSPITAL SURVEY REGARDING
PATIENT-CONTROLLED ANALGESIA
2.1 Introduction
In the 21st century, with continuous increase in technological advancements, elec-
tronic healthcare monitoring has increased leaps and bounds. Although, current
patient monitoring systems are now easier to use and can be rapidly deployed, there
might be some challenges with its use if practitioners are not kept up-to-date with
technology, if standard practices are not followed, or if there are other non-medical
errors in the procedure.
A national survey of the United States hospitals regarding practices around patient-
controlled analgesia (PCA) pump administration was carried out to begin to address
some of the issues with electronic monitoring. Such survey analysis has never been
conducted. Using PCA pumps to help manage patients’ pain has become accepted
medical practice and is generally considered safe and effective. In its Sentinel Event
Alert, “Safe Use of Opioids in Hospitals” [18], the Joint Commission recommends the
use of PCA to help avoid adverse events associated with the use of opioids. In the
same Sentinel Event alert, the Joint Commission also warns against the possibility
of opioid-induced respiratory depression (OIRD): “While opioid use is generally safe
for most patients, opioid analgesics may be associated with adverse effects. The most
serious effect being respiratory depression, which is generally preceded by sedation”.
Fifty percent of Code Blue events involve patients receiving opioid analgesia [19].
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Unrecognized postoperative respiratory failure that results in cardiopulmonary arrest
is a daily occurrence at healthcare facilities across the United States. Since cardiopul-
monary arrest often results in death or anoxic brain injury, these events have been
termed “failure to rescue”. Failure to rescue is the first and third most common cause
of adverse events related to patient safety, accounting for 113 events per 1,000 at-risk
patient admissions [20].
In his recent presentation at the Patient, Safety Science & Technology Summit
[21], Robert Stoelting, MD (President, Anesthesia Patient Safety Foundation) stated
that more than 13 million patients each year receive PCA in the United States. Esti-
mates of respiratory depression range from 0.16 percent to 5.2 percent of all patients.
This means that each year between 20,800 to 676,000 PCA patients could experi-
ence opioid-induced respiratory depression. As Dr. Stoelting explains, “Clinically
significant drug-induced respiratory depression (oxygenation and/or ventilation) in
the postoperative period remains a serious patient safety risk that continues to be
associated with significant morbidity and mortality” [22].
The focus of this study is to identify risk factors for health care practices that
may be critical to a large number of adverse events in patients on PCA after surgery.
2.2 Statistical Inference and Survey Design
The main idea of statistical inference is to take a random sample from a population
and use this information from the sample to make inferences about particular popu-
lation characteristics such as the mean (measure of central tendency), the standard
deviation (measure of spread) or the proportion of units in the population that have a
certain characteristic. Sampling saves time, money, and effort. Additionally, a sample
can, in some cases provide as much information as a corresponding study that would
attempt to investigate an entire population -careful collection of data from a sample
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will often provide better information than a less careful study that tries to look at
everything. The behavior of the mean of sample values from different specified popu-
lations must be specified. Because a sample examines only part of a population, the
sample mean will not exactly equal the corresponding mean of the population. Thus,
an important consideration for the planning and interpretation of sampling results,
is the degree to which sample estimates, such as the sample mean, will agree with
the corresponding population characteristic. In practice, only one sample is usually
taken; however, there are instances in other survey data analysis, that a small pilot
sample is used to test the data-gathering mechanisms and to get preliminary infor-
mation for planning the main sampling scheme. For the purposes of understanding
the degree to which sample means will agree with corresponding population mean, it
is useful to consider what would happen if 10 or 50 or 100 separate sampling studies,
of the same type, were conducted. If results from each of the samples show to be
nearly the same, confidence is gained in the single sample that will actually be used.
On the other hand, seeing that answers from the repeated samples are too variable
for the needed accuracy, would suggest that a different sampling plan (perhaps one
with a larger sample size) should be used.
In this study, a cross-sectional sampling technique was used to study the obser-
vation of a defined population (hospitals) at a single point in a time interval (March
and April 2013). Both exposure and outcome were determined simultaneously.
2.3 Statistical Theory
2.3.1 Linear Regression vs. Non-Linear Regression
Linear Regression models or models that are linear in the parameters, are used
to study the association independent variables have on a dependent variable. Linear
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regression models include not only first-order models in p-1 predictors variables but
also more complex models. For example, a polynomial regression model in one or
more predictor variables is linear in the parameters, such as the following model in
two predictor variables with linear, quadratic, and interaction terms:
Yi = β0 + β1Xi1 + β2X
2
i1 + β3Xi2 + β4X
2
i2 + β5Xi1Xi2 + i (2.1)
Also, models with transformed variables that are linear in the parameters belong to
the class of linear regression models, such as the following model:
log10Yi = β0 + β1
√
Xi1 + β2exp(Xi2) + i (2.2)
In general, a linear regression model can be expressed in the following form:
Yi = f(Xi, β) + i (2.3)
where Xi is the vector of the observations on the predictor variables for the ith case:
Xi =

1
Xi1
.
.
.
Xi,p−1

(2.4)
β is the vector of the regression coefficients, and f(Xi, β) represents the expected value
E(Yi) which for linear regression models equals f(Xi, β) = Xi
′β Nonlinear regression
models are of the same basic form as that for linear regression models:
Yi = f(Xi, γ) + i (2.5)
An observation Yi is still the sum of a mean response Yi = f(Xi, γ) given by the
nonlinear response function f(Xi, γ) and the error term i. The error terms usually
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are assumed to have expectation zero, constant variance, and to be uncorrelated, just
as for linear regression models. Often, a normal error model is utilized which assumes
that the error terms are independent normal random variables with constant variance.
The parameter vector in the response function f(Xi, γ) is now denoted by γ rather
than β to denote that the response function here is nonlinear in the parameters.
2.3.2 Logistic Regression
An important nonlinear regression model is the logistic regression model. This
model with one predictor variable and normal error terms is:
Yi =
γ0
1 + γ1exp(γ2Xi)
+ i (2.6)
where the error terms i are independent normal with constant variance σ
2, and the
response function is not linear in the parameters. The response function is:
f(X, γ) =
γ0
1 + γ1exp(γ2X)
(2.7)
A model like this is used in population studies to relate number of species Y to
time X. However, when the response variable is qualitative, the error terms are
not normally distributed with constant variance, and this poses constraints on the
response function. If we consider the simple linear regression model:
Yi = β0 + β1Xi + i, for Yi = 0, 1 (2.8)
where the outcome Yi is binary, taking on the value of either 0 or 1. The expected
response E(Yi) has a special meaning in this case. Taking the E(i) = 0 we end up
with:
E(Yi) = β0 + β1Xi (2.9)
Since Yi takes on two values, we consider it to be a Bernoulli random variable for which
pii is the probability that Yi = 1 and 1− pii is the probability that Yi = 0. Using the
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definition of expectation for a random variable, we obtain E(Yi) = 1(pii)+0(1−pii) =
pii = P (Yi = 1). Thus, E(Yi) = β0 + β1Xi = pii. The mean response, when the
outcome variable is a 0, 1 indicator variable, always represents the probability that
Y = 1 for the given levels of the predictor variables.
2.3.3 Constraints with a Binary Response Variable
When the response variable is an indicator variable, special problems arise. The
first is nonnormal error terms. For a binary 0,1 response variable, each error term
i = Yi − (β0 + β1Xi) can only take on two values:
i = 1− β0 − β1Xi, when Yi = 1 :
i = −β0 − β1Xi, when Yi = 0 :
(2.10)
This is an indication that a normal error regression model, which assumes that i are
normally distributed, is not appropriate.
The second is nonconstant error variance. The error terms i do not have equal
variances when the response variable is an indicator variable. If we obtain the σ2(Yi)
for the simple linear regression model:
σ2(Yi) = E[(Yi−E(Yi)]2) = (1 = pii)2pii+(0−pii)2(1−pii) = pii(1−pii) = (E(Yi))(1−E(Yi))
(2.11)
which is equal to:
σ2(Yi) = (β0 + β1Xi)(1− β0 − β1Xi) (2.12)
This error depends on Xi which means that the error terms will differ at different
levels of X, and ordinary least squares will not be optimal.
The third is the constraint on the response function. Since the mean response
function represents probabilities when the outcome variable is a 0, 1 indicator variable,
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the mean responses should be constrained as follows:
0 ≤ E[Y ] = pi ≤ 1 (2.13)
Many response functions do not possess this constraint, and this is the most serious
of the three. Using weighted least squares could be a potential solution to unequal
error variances. Additionally, with large sample sizes the method of least squares
provides estimators that are asymptotically normal under quite general conditions,
even if the distribution of the error terms is far from normal. The constraint on the
mean response to fall between 0 an 1, however, rules out a linear response function.
2.3.4 Response Functions for Binary Responses
There are several response functions used for modeling binary responses. These
functions are bounded between 0 and 1, have a characteristic sigmoidal (S-shape), and
approach 0 and 1 asymptotically. Some of these include the Probit Mean Response
Function (which uses the standard normal cumulative distribution function to model
pii), the Logistic Distribution (which uses the density of a logistic random variable L
having mean zero and standard deviation σ = pi√
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to model the P (Yi = 1)), and the
Log-Log Response Function (used when the error distribution is not symmetric). For
the survey analysis in this dissertation, some of the analyses required using Logistic
Regression.
Focusing on Logistic Regression, the method of maximum likelihood is used to
estimate the parameters of the logistic response function. Since Yi is a Bernoulli
random variable where P (Yi = 1) = pii and P (Yi = 0) = 1−pii, its likelihood function
can be represented as:
L =
n∏
i=1
piYii (1− pii)1−Yi (2.14)
The maximum likelihood estimates of β0 and β1 in the simple logistic regression model
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are those values of β0 and β1 that maximize the log-likelihood function. No closed-
form solution exists for the values of β0 and β1 that maximizes the log-likelihood
function, and as a result computer intensive numerical search procedures are required
to find the maximum likelihood estimates β0 and β1. Once the maximum likelihood
estimates b0 and b1 are found, these values are substituted into the response function
to obtain the fitted value which is equal to the estimated probability for the ith case.
pii =
exp(b0 + b1Xi)
1 + exp(b0 + b1Xi)
(2.15)
In the survey data analysis, most of the results are presented as Odds Ratios (OR),
which after mathematical derivation equal exp(b1) in a simple linear regression. In
the case of multiple logistic regression, the fitted values become:
pii =
exp(X ′β)
1 + exp(X ′β)
(2.16)
The Odds Ratios can be derived the same way as in the case of simple linear regres-
sion, for example exp(b2) would be the odds ratio for the variable X2 provided that
everything else in the model stays constant.
In order to address the specific questions of the survey and find associations,
Logistic Linear Regression was used.
2.4 Methodology
During March and April 2013, this national survey of hospitals was conducted
regarding practices related to PCA by A Promise to Amanda Foundation and the
Physician-Patient Alliance for Health & Safety. The survey questions were prepared
with the assistance and input from the individuals listed on Appendix A. The survey
was distributed through The Institute for Healthcare Improvement Hospital Networks
and Hospital Members of the Premier Safety Institute. Survey questions consisted
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of demographic information (position, profession, location), risk factors considered
before administration of PCA (obesity, low body weight, concomittant medications
that potentiate sedative effects, advanced age, opioid naive, pre-existing conditions
such as asthma, copd, sleep apnea) and PCA training and use (see Appendix B for
the list of survey questions). Because all orders for PCA at any given institution must
be processed by a pharmacist, hospital-based pharmacists were targeted to answer
the survey. Consequently, most of the survey respondents identified themselves as
hospital pharmacists (47%). Although this may lend itself to bias towards pharma-
cists, this likely means that the responses were representative of the hospital rather
than an individual respondent’s perspective. The remaining respondents identified
themselves as either physicians (18%) or a non-physician healthcare provider, such as
a nurse or respiratory therapist (35%). The 168 United States respondent hospitals
represented the diversity of hospitals across the United States. Respondent hospitals
were geographically dispersed and came from 40 of the 50 United States. Moreover,
they varied in size, from as small as 14 beds to the largest having more than 1,500
beds, with the median hospital having 200 beds.
The respondent hospitals were more representative of teaching hospitals than non-
teaching hospitals (55%) than non-teaching hospitals (45%). In the U.S., teaching
hospitals represent 1,000 of the more than 5,000 hospitals in the U.S., or approxi-
mately 20%. [23]. However, this possible bias towards teaching hospital respondents
may suggest that the survey results could be more reflective of future practice stan-
dards rather than current, as students leave these institutions to practice medicine at
non-teaching hospitals. Teaching hospitals ”provide clinical education and training to
medical students, residents, and postgraduate fellows and are distinguished, in large
part, by their clinical research programs, where drugs, medical devices and treatment
methods are developed and tested” [23].
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2.5 Statistical Analysis
The survey consisted of binary (Yes or No) responses, choice responses or open-
ended responses. Binary responses were coded as 1 for Yes and 0 for No, while the
questions that provided choices were coded as categorical numerical values. For the
questions that were open-ended responses, these were clustered based on similarity of
responses and were coded as categorical numerical responses.
Logistic regression was used to estimate the different associations involving PCA
use, training, or monitoring. Odds ratios (OR) and 95% confidence intervals (CIs)
were also estimated. Findings for statistical analyses were systematically recorded in
Table 2.1 and implications from the study were collected. As well, we report two-sided
p-values in support of finding associations in either direction.Statistical analyses were
conducted using SAS release 9.3 (SAS institute, Cary, NC).
2.6 Key Clinical Insights
Survey responses provide key clinical insights into the following three processes or
practice areas: (1) how the use of a standard risk factor assessment prior to initiating
opioid administration could help reduce opioid-induced respiratory depression, (2) the
role continuous electronic monitoring could play in decreasing hospital expenses and
improving workflow, (3) the tools and training hospitals think they need to combat
alarm fatigue. Each process area is discussed in the following sections.
2.6.1 Risk Factor Assessment
Many respected healthcare organizations have provided warnings that safe PCA
use starts with selecting suitable patients. In discussing this issue of patient selec-
tion, the Pennsylvania Patient Safety Authority in its analysis of approximately 4,500
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Characteristics of Patients Who Are At Higher Risk for Oversedation and Res-
piratory Depression
Sleep apnea or sleep disorder diagnosis [22, 23, 36]
Morbid obesity with high risk of sleep apnea [22, 23]
Snoring [22, 23]
Older age: risk is
† 2.8 times higher for individuals aged 61-70
† 5.4 times higher for individuals aged 71-80
† 8.7 times higher for individuals over 80 [22, 29, 37]
No recent opioid use [23, 38]
Post-surgery, particularly if upper abdominal or thoracic surgery [22, 39]
Increased opioid dose requirement [23] or opioid habituation
Longer length of time receiving general anesthesia during surgery [22, 39]
Receiving other sedating drugs, such as benzodiazepines, antihistamines,
diphenhydramine, sedatives, or other central nervous system depressants [21, 23, 25, 29]
Pre-existing pulmonary or cardiac disease or dysfunction or major organ failure [22, 23]
Thoracic or other surgical incisions that may impair breathing [22, 23]
Smoker [22, 23]
Table 2.2: Characteristics of Patients Who Are At Higher Risk for Oversedation
and Respiratory Depression
event reports it received from June 2004 through May 2010 provides the following
caution: “...candidates for PCA should have the mental alertness and cognitive ability
to manage their pain and communicate their pain level to their caregiver”. Moreover,
the Joint Commission in its Sentinel Event Alert #49 “Safe Use of Opioids in Hospi-
tals” [18] provides the following chart showing characteristics of patients who are at
higher risk of over-sedation and respiratory depression [see Table 2.2].
To determine which patient risk factors are assessed by hospitals prior to the initi-
ation of PCA, the survey provided a short list of factors identified in the PCA Safety
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Checklist. This recently developed checklist was accomplished with the assistance of
a group of renowned health experts assembled by the Physician-Patient Alliance for
Health & Safety. Respondents were asked whether before initiating patients on PCA,
the following patient risk factors were considered: Obesity, Low Body Weight, Con-
comitant Medications that Potentiate Sedative Effects of Opiate PCA, Pre-existing
Conditions (such as asthma, COPD, sleep apnea), Advanced Age, and Opioid Naive.
The survey found that, although patient risk factors are considered, this is not being
done by every hospital, with every patient, as indicated in the Figure 3 in Appendix
C.
This suggests that there is a tremendous variation between the treatments being
received by patients across the country with more than 60 percent of respondents
considering five or less factors, and less than 40 percent indicating that they were
considering all six patient risk factors. To illustrate the dangers of not considering
a particular patient risk factor, an analysis was conducted against recommended
practice. Three of these risk factors were chosen: opioid naive, obesity, and advanced
age. These are discussed in the following sections.
2.6.2 Opioid Naive Patients
The National Comprehensive Cancer Network defines opioid naive patients as
those “who are not chronically receiving opioid analgesic on a daily basis” [26]. Con-
sequently, because opioid naive patients are at greater risk for over-sedation and
respiratory depression, the Joint Commission recommends taking “extra precautions
with patients who are new to opioids or who are being restarted on opioids” [18]. Clin-
ically significant to point out are the survey’s findings which indicated that almost
one out of five hospitals are not assessing patients for being opioid naive. Addition-
ally, pharmacists were four times more likely to consider opioid naive as a risk factors
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versus other healthcare professionals (OR=4.07, 95 %CI: 1.59-10.43). Noteworthy
to mention that physicians were approximately 70 percent less likely than the other
types of respondents to say that they consider opioid naive as a patient risk factor
(OR=0.32, 95 % CI: 0.13 - 0.79). This is indicative of a greater need for awareness
among physicians to the heightened risk of the use of opioids in opioid naive patients.
The survey findings suggest that some opioid naive patients may be receiving PCA
when they have not adequately and thoroughly been assessed and determined they
are at too high of risk for adverse event occurrence.
2.6.3 Obesity
About three out of 10 hospitals do not consider obesity as a clinically signifi-
cant patient risk factor, despite the indications of many studies that have shown the
increased risk of using anesthesia with obese patients [27]. As researchers have stated:
One of the many problems in providing anaesthesia for morbidly obese
patients is the influence of obesity on pharmacokinetics and pharmaco-
dynamics. Drug administration in obese patients is difficult because rec-
ommended doses are based on pharmacokinetic data obtained from in-
dividuals with normal weights; therefore, mistakes in the determination
of the appropriate dose are often made. Because of comorbidity in these
patients, the function of organs involved in drug elimination (e.g., kidney,
liver) can be affected making pharmacokinetics more difficult and complex
[28].
The survey findings suggest that some obese patients may be receiving PCA when
perhaps they should not be due to inadequate patient risk assessment.
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2.6.4 Advanced Age
The risk of respiratory depression increases substantially for patients over 60 years
of age. The Joint Commission cautions against the use of opioids in older patients
because of the heightened risk of over-sedation and respiratory depression with the risk
being approximately 2.8 times higher for individuals aged 61-70, 5.4 times higher for
individuals aged 71-80, and 8.7 times higher for individuals over age 80 [18]. Presently,
not all healthcare facilities consider advanced age as a risk factor with about three
out of every 20 hospitals not assessing their patients using PCA for advanced age.
Significantly, at those hospitals that provide on-going training in PCA admin-
istration, advanced age was more likely to be considered a patient risk factor that
potentially poses greater risk of over-sedation and respiratory depression to the pa-
tient. This suggests that the clinical imperative is to have active on-going PCA ad-
ministration training for all healthcare professionals using PCA as the pain modality
treatment.
2.6.5 Continuous Monitoring
Continuous electronic monitoring with pulse oximetry for oxygenation and capnog-
raphy for adequacy of ventilation is recommended for greater patient safety. As Dr.
Stoelting states in discussing patient safe measures to be used for patients using PCA:
APSF recommends that monitoring be continuous and not intermittent,
and that continuous electronic monitoring with both pulse oximetry for
oxygenation and capnography for the adequacy of ventilation be consid-
ered for all patients [28]
Despite these recommendations, patients are not monitored with either pulse
oximetry or capnography at over three out of every 20 hospitals (16.07 %). How-
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ever, of the hospitals that are not electronically monitoring any of their patients,
almost nine out of 10 (86.7 %) say they are considering the use of monitoring. This
suggest that continuous electronic monitoring may likely become a standard proce-
dure. Though, time of adoption in some cases may be long and the assessment of use
of additional electronic monitoring systems may be required. There is predominance
of hospitals monitoring their patients using PCA wth pulse oximetry with more than
one out of every two using just oximetry (50.6 %) to monitor all or some of their
patients. Two out of three hospitals (66.67 %) are using a mix of pulse oximetry and
capnography.
In terms of greater patient safety significance and for hospitals that have identified
cost and expense reduction, the clinical change that has occurred are in hospitals
that are continuously electronically monitoring their patients with pulse oximetry
and/or capnography. Of the respondent hospitals that continuously monitor their
patients receiving PCA, 65 percent have experienced positive results–either in terms
of a reduction of overall adverse events or a return on investment when measured
against cost expenditures (including litigation costs). The other 35 percent of those
that monitor say it is “too early to determine or have not determined” whether they
have seen a reduction in adverse events, costs, or expenses.
While the merits or demerits of using pulse oximetry or capnography has been
much debated, the survey results indicate the clinical value of patient surveillance
monitoring, as has been suggested by research conducted by Andreas Taenzer, MD,
and his colleagues at the Dartmouth-Hitchcock Medical Center [30]. Patient surveil-
lance monitoring, where all patients are continuously electronically monitored, is
distinct from condition monitoring where some patients are selected for monitoring
without defined clinical criteria. As Frank Overdyk, MD, writes in describing this
work at Dartmouth:
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In their review of the approaches to address fail failure-to-rescue (FTR),
Dr. Andreas Taenzer and his colleagues found that previous attempts [32]
have largely focused, with limited success, on improving the response to
an identified patient crisis. Such approaches have led to the development
of rapid response teams (RRTs). However, the primary determinant for
the success of RRTs have been found to be early recognition and this is
where continuous electronic monitoring may provide an early detection
solution [31].
Moreover, when we analyzed the type of smart pump being used at the facilities
reporting a decline in adverse events or a return on investment, there was a significant
correlation with those using smart pumps with integrated end tidal monitoring. Those
using smart pumps with integrated end tidal monitoring were almost three times
more likely to have had a reduction in adverse events or a return on investment when
measured against costs and expenses (including litigation costs) that might have
been incurred (OR=2.79; 95% CI: 1.11 - 6.99). The positive experience in terms of a
reduction in adverse events and costs, and the use of integrated end tidal monitoring
that was reported by survey respondents mirrors the experience of other hospitals
that have instituted continuous monitoring of their patients, like St. Joseph/Candler
Hospitals (SJ/C) in Savannah, Georgia. Harold Oglesby, RRT, manager of respiratory
care at SJ/C [33]. He describes how his hospital has had more than eight years
of event-free use of PCA using “smart” PCA pumps with integrated capnography
monitoring:
A lot of the information comes from the research that we’ve done that
has been focused on PCA patients monitored with capnography and the
effectiveness gained in monitoring ventilation versus oxygenation. What
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we found is that we have an earlier recognition of any patient deterioration
using capnography versus using oximetry alone. We also have looked at
several case studies of patients, and we noted that by the use of capnogra-
phy, we’ve recognized deteriorating patients early; so it gives us the leeway
to take actions before those patients get into any trouble.
Moreover, although a human life should never be measured in dollars and cents, St.
Joseph’s/Candler Hospitals caculated that their decision made great financial sense
with $4 million - estimated potential expenses averted (not including potential litiga-
tion costs) and $2.5 million - 5-year return on investment [34]. From an engineering
perspective, this “closed-loop” system of having the capnography monitor integrated
with the PCA pump has been described as the ideal patient safety guard rail. A PCA
pump with integrated end tidal monitoring allows the pump to automatically shut off
when the monitor senses that the patient is becoming oversedated. Bryanne Patail,
biomedical engineer at the U.S. Department of Veterans Affairs, National Center for
Patient Safety, explains what the Veterans Health Administration has done to reduce
errors related to PCA use and improve patient safety [35]:
Use of PCA pumps is a process, and improving that process is an area that
involves many stakeholders. In looking at fixes, they can be categorized
as strong, intermediate or weak fixes. The strongest fix for PCA pumps
is a forcing function, such as an integrated end tidal CO2 monitor that
will pause the pump if a possible over infusion occurred. So, healthcare
providers should first look at these strong fixes. There they will see the
most impact on reducing errors and improving patient safety.
The survey results strongly suggest that using PCA pumps with integrated end
tidal monitors will greatly improve patient safety.
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2.6.6 Alarm Fatigue
According to The Joint Commission, alarm fatigue occurs when clinicians become
de-sensitized or immune to the sound of an alarm [36]. Fatigued clinicians may turn
down alarm volume, turn off alarms, or adjust alarm settings. Concern about alarm
fatigue was extremely high, with only less than one in 20 hospitals (4.9 %) saying
that they were “not concerned at all”. The vast majority (more than 95 %) are
concerned about the issue of alarm fatigue, with 61.3 percent reporting that they
are concerned but don’t believe alarm fatigue is an “unmanageable problem”. With
almost two out of three hospitals seeing alarm fatigue as ”manageable”, this bodes
well for the successful achievement of The Joint Commission’s national patient safety
goal to manage alarms [37].
About one out of three hospitals (33.7 %) are either concerned that alarm fatigue
will be a problem that is difficult to manage or the potential for alarm fatigue is
preventing them from implementing continuous electronic monitoring. This indicates
that for these hospitals, the issue of alarm fatigue is negatively impacting work pro-
cesses and the safety of their patients. Almost nine out of ten hospitals (87.8 %)
believe that a reduction of false alarms would increase the use of patient monitoring
devices, such as oximeter or capnograph. Alarm fatigue and the need for improved
alarm sound management is therefore preventing hospitals from implementing contin-
uous electronic monitoring as a patient safety measure which would provide reduction
in adverse events, costs and expenses. In the following analysis, three levels of concern
with alarm fatigue have been used: Not concerned about alarm fatigue (4.9 % of hos-
pitals), Concerned alarm fatigue is an unmanageable problem (33.73 % of hospitals),
and Managing alarm fatigue (61.4 % of hospitals).
To help manage alarm fatigue, hospitals indicate that tools and training would
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be of assistance. Seven out of 10 hospitals (70.7 %) would like “a single indicator
that accurately incorporates key vital signs, such as pulse rate, SpO2, respiratory
rate, and etCO2”. Additionally, almost half of the respondents (44.6 %) would like
“recommendations on how best to easily make such assessments” of patients, and
more than half (52.9 %) would like to see more clinical training. However, those
concerned that alarm fatigue is an unmanageable problem were more than twice as
likely to want a single-indicator assessment tool (OR=2.04; 95% CI: 1.07 - 4.84) and
recommendations for ease of assessment for their nursing staff (OR=2.04; 95% CI:
0.99 - 4.19). This indicates that nursing staff may be having difficulty interpreting
the data. This does not suggest a lack of knowledge (as there was not statistically
significant correlation with a desire for more clinical training for nurses), but that
the amount of data needing to be interpreted may be overwhelming. The volume of
data about a patient together with the sheer number of alarms is a critical patient
safety issue. The survey indicates that providing tools to address patient assessment,
with both a technological aid to gather multiple parameters into a single indicator,
as well as recommendations for easily assessing a patient, would assist with alarm
management.
2.7 Conclusions
The survey results indicate three key areas where patient safety could be improved.
First, the results demonstrate great variance in patient risk factors assessed which
indicate great concern for the safety of patients from one institution to the next.
Standardization of practices where every patient is assessed before initiating PCA
would be of great assistance, according to Ana Pujols McKee, MD, executive vice
president and chief medical officer, The Joint Commission:
The Joint Commission recognizes there is an opportunity to improve care
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for patients by improving the safety of opioid use in acute care settings
given that data show opioids are among the top three drugs in which
medication-related adverse events are reported. Opioids are necessary to
prevent suffering, but there are risks related to potency, route of admin-
istration, and patient history. By engaging in a comprehensive approach
to assessment, monitoring, and patient education, opioid overuse and as-
sociated harm can be prevented [38].
The PCA Safety Checklist [39], which was developed with the help of a panel of
health experts [25], contains one example of a risk factor assessment tool for evaluating
patients. Second, the survey results also show that continuous electronic monitoring
has reduced adverse events and hospital expenditures. Although continuous electronic
monitoring is not universally applied for all patients receiving opioids, hospitals that
do not monitor their patients should consider doing so, not only to improve patient
safety, but to decrease their expenses. Lastly, although alarm fatigue is a concern
of hospitals, clinical training and the use of a single assessment indicator have been
indicated as two items that hospitals would like to better manage alarms.
This survey is a first national effort to gather data on PCA practices. Subsequent
surveys could look further into the use of risk factor assessment tools in evaluating
respiratory compromise, protocols for continuous monitoring, and how reducing alarm
fatigue expends the use of continuous monitoring.
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Chapter 3
EFFECT OF BENIGN PROSTATIC HYPERTROPHY ON SLEEP
ARCHITECTURE AND SEVERITY OF SLEEP APNEA IN MEN WITH
OBSTRUCTIVE SLEEP APNEA VIA A SIMPLE NOVEL STATISTICAL
MODELING APPROACH
3.1 Introduction
Obstructive Sleep Apnea (OSA) is a common sleep disorder characterized by mul-
tiple cessations of breath during sleep, which cause intermittent hypoxia (IH) and
sleep fragmentation. Each cessation of breath, referred to as an apnea, can last from
10 seconds to minutes. Sleep Apnea can be mild, moderate, or severe, according to
the number of apneas per hour [2]. OSA is a common disorder that is ofthen asmp-
tomatic; the prevalence of patients with OSA who do not present clinical syndrome,
might be as high as 20% to 30% in the middle-aged [3]. IH is one of the major patho-
logical conditions to affect OSA patients, and chronic IH can activate inflammatory
pathways [4]. A meta-analysis showed that systematic pro-inflammatory cytokines
and inflammatory markers are elevated in OSA patients [5]; OSA may therefore be
considered as a systematic inflammatory disease [6]. Benign Prostate Hyperplasia
(BPH) is one of the most common chronic conditions in the male population with a
histological prevalence at autopsy of 50% in men aged 50-60 years and 90% in men
aged over 80 years [7]. Although the pathogenesis of BPH is unknown, data suggest
a possible role of chronic inflammation in BPH [8] as suggested by inflammatory el-
ements in surgically treated BPH [9]. A recent study indicates that patients with
OSA are associated with increased longitudinal risk of BPH development, and that
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the effects of OSA on BPH development are age-dependent. Treatment of OSA and
BPH [10] improve sleep quality by subjective measurements and scales. We aim to
objectively evaluate the effect of BPH on sleep architecture in patients with OSA
diagnosed by polysomnography.
3.2 Materials and Methods
3.2.1 Study Design and Population
All adults (> 18 years of age) male patients who were referred for polysomnog-
raphy (PSG) first time for clinically suspected OSA by sleep clinic physicians at
James A Lovell Federal Healthcare Center who were found to have OSA by sleep
study during January 01, 2009, to December 31, 2011, were recruited for the study.
BPH was clinically diagnosed by the primary care physician of the patient in some
of these subjects. Data for both groups (OSA and OSA with BPH) was collected
from computerized patients’ record system (CPRS) for the demographic variables;
age and body mass index (BMI). Each patient was diagnosed to have OSA by PSG
(Somnostar-Pro 7-3A; Carefusion) and sleep stages were scored according to rules
described by the Rechtschaffen and Kales (R & K) scoring manual [14] by the reg-
istered polysomnographic technologist. Data recorded from the sleep study included
the following sleep characteristics: total sleep time (TST), sleep efficiency (SE), OSA
severity (Apnea-Hypopnea index (AHI)) and Rapid Eye Movement Sleep AHI (REM-
AHI), sleep stages (Percent of time spent in Stage 1, Stage 2, Stage 3 and 4, REM
sleep), Arousal Index (AI), Sleep and REM Onset. Here, we develop statistical mod-
els using the clinical data to estimate model parameters. The simulated data from the
model were used to study research questions and to derive robustness in implications.
Throughout the paper, we will call “original data” to refer data obtained directly
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from the patients, and “simulated data” to refer the sample data from models.
This OSA study was approved by the Institutional Review Board at Rosalind Franklin
University for Medicine and Science located in North Chicago, Illinois. The Institu-
tional Review Board approved conduct of the research without explicit consent from
the participants and ethical guidelines were followed in the study.
3.3 Statistical Analysis
This retrospective study reviews 62 subjects with OSA diagnosed by PSG who
had BPH (cases) and 62 patients with OSA diagnosed by PSG who did not have
BPH (controls). In determining the effect of BPH on sleep architecture in patients
with obstructive sleep apnea, we calculated and reported means of the sleep measure
variables by case-controls status using a two-sample t-test using original data (Table
3.1). The total sample (62 cases + 62 controls) primarily consisted of obese (BMI
32.6 ± 5.11), and older (Age 63.06 ± 11.11) subjects. Subjects with BPH have higher
age (67.11 ± 9.81 versus 59.01 ± 10.92, p < 0.001) but similar BMI (32.39 ± 4.92
versus 32.8 ± 5.33, p < 0.65).
Table 3.1 shows that time spent sleeping in stage 1 was found to be significantly
different between both groups. Those patients with BPH demonstrated to have longer
stage 1 (27.5 versus 21.1 % of total sleep time , p=0.03). This shows that those with
BPH have additional reason for sleep interruption, which translates into more light
stage (stage I) sleep and less stage 2 or 3 and 4. Although not statistically different,
Table 3.1 also shows that controls have higher total sleep time, sleep efficiency, and
time spent sleeping in REM stage, while stage 2, stage 3 and 4 were similar.
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3.4 Bootstrapping Approach
A specific bootstrapping sampling approach was developed to determine functional
form of each of the variables in the original data. Since each of the subjects are
different and their sleep measures were independently collected, we assumed that each
sleep measure were independent and identically distributed. As a result, assumptions
about the functional forms of probability distributions of the error terms were made
for each of the sleep measures. The maximum likelihood estimation approach, which
is significantly robust to deviations from model assumptions, was used to estimate
the parametric distributions for each of the sleep apnea variables defined both under
cases and controls. As such, all valid parametric distributions were fitted to each of
the sleep measures under cases and under controls. The top five distributions were
then sorted on a metric used to compare the goodness of fit- each derived from its
own distribution. Goodness of fit criteria used in the selection process consisted of the
Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), the small
sample size version of the Akaike Information Criterion (AICc), and the Negative Log
Likelihood (NLogL) [1]:
AIC = −2 ∗ log(L(y|x)) + 2p (3.1)
where log(L(y|x)) represents the log likelihood as the product of the densities viewed
as a function of the unknown parameters, and p represents the number of parameters.
BIC =
RSSp
σ
+ logn ∗ p (3.2)
where RSS is the residual sum of squares.
AICc = n ∗ log(2piσˆ2) + n(n+ p)
n− p− 2 (3.3)
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NLogL = −log(L(y|x)) (3.4)
The list of parametric distributions for fitting original sleep measure data corre-
sponding to continuous variables that were considered consisted of: Beta, Birnbaum-
Saunders, Exponential, Extreme Value, Gamma, Generalized Extreme Value, Gener-
alized Pareto, Inverse Gaussian, Logistic, Log-logistic, LogNormal, Nakagami, Rayleigh,
Rician, T Location-Scale, and Weibull. Following are descriptions and applications of
these distributions. The following distributions were derived from Casella and Berger
[1].
The Beta family of distributions is a continuous family on the set (0,1) indexed
by the two parameters α and β. The beta(α, β) pdf is:
f(x|α, β) = 1
B(α, β)
xα−1(1− x)β−1, 0 < x < 1, α > 0, β > 0, (3.5)
where B(α, β) denotes the beta function:
B(α, β) =
∫ 1
0
xα−1(1− x)β−1dx. (3.6)
where the beta function is related to the gamma function through B(α, β). The beta
function is one of the few distributions that give probability 1 to a finite interval, here
taken to be (0,1).
The Birnbaum-Saunders distribution is also known as the fatigue life distribution
used to model failure times. The pdf is:
f(x|µ, β, γ) =
√
x−µ
β
+
√
β
x−µ
2γ(x− µ) φ
 √x−µβ −
√
β
x−µ
γ
 x > µ; γ, β > 0 (3.7)
The Exponential distribution known to describe the time between events in a
Poisson process (a process where events occur continously ad independently at a
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constant average rate). The exponential distribution is also a special case of the
gamma distribution, and has the key property of being memoryless.
f(x|β) = 1
β
e
−x
β , 0 ≤ x <∞, β > 0 (3.8)
The Extreme Value distribution is suitable for modeling the minimum value. To
model the maximum value, use the negative of the original values. Its pdf:
f(x|µ, σ) = σ−1exp
(
x− µ
σ
)
exp
(
−exp
(
x− µ
σ
))
(3.9)
The Gamma distribution is also frequently used to model waiting times. Its pdf:
f(x|α, β) = 1
Γ(α)βα
xα−1e
−x
β , 0 < x <∞, α > 0, β > 0 (3.10)
The Generalized Extreme Value distribution is the only possible limit distribu-
tion of properly normalized maxima of a sequence of independent and identically
distributed random variables; It is often used as an approximation to model the max-
ima of long (finite) sequences of random variables.
f(x|µ, σ, ξ) = 1
σ
t(x)ξ+1e−t(x), where t(x) =
(
1 +
(
x− µ
σ
)
ξ
)−1
ξ
if ξ 6= 0, e−(x−µ)σ if ξ = 0
(3.11)
The Generalized Pareto distribution is often used to model the tail of another
distribution. Its pdf:
f(x|µ, σ, ξ) = 1
σ
(
1 + ξz)−
1
ξ
+1
)
, where z =
x− µ
σ
(3.12)
The Inverse Gaussian distribution is used as a model for response times in psy-
chology. Its pdf:
f(x|µ, λ) =
(
λ
2pix3
) 1
2
exp
−λ(x− µ)2
2µ2x
, where x > 0, µ > 0 , and λ > 0. (3.13)
The Logistic distribution is applicable to many areas. One of the most common
applications is in logistic regression, which is used for modeling categorical dependent
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variables. Its pdf
f(x|µ, β) = 1
β
e
−(x−µ)
β(
1 + e
−(x−µ)
β
)2 , −∞ < x <∞, −∞ < µ <∞, β > 0 (3.14)
The Log-Logistic distribution is a continuous probability distribution for a non-
negative random variable. It is used in survival analysis to model events whose rate
increases initially and decreases later, for example mortality rate from cancer following
diagnosis or treatment. It is similar to a log-normal distribution but has heavier tails.
Its pdf
f(x|α, β) = (
β
α
)( x
α
)β−1
(1 +
(
x
α
)β
)2 , x > 0, α > 0, β > 0 (3.15)
The Lognormal distribution is a continuous probability distribution for a random
variable whose logarithm is normally distributed. A random variable which is log-
normally distributed takes only positive real values. It is important in the description
of natural phenomena such as growth and used to analyze extreme values of such
variables as monthly and annual maximum values of daily rainfall. Its pdf
f(x|µ, σ2) = 1√
2piσ
e
−(log x−µ)2
2σ2
x
, 0 ≤ x <∞, −∞ < µ <∞, σ > 0 (3.16)
The Nakagami distribution is a probability distribution related to the gamma
distribution. Being first proposed in 1960, it is relatively new and has been used to
model attenuation of wireless signals traversing multiple paths. Its pdf
f(x|m,Ω) = 2m
m
Γ(m)Ωm
x2m−1exp
(
−m
Ω
x2
)
, m ≥ 0.5, Ω > 0 (3.17)
The Rayleigh distribution is a continuous probability distribution for positive-
valued random variables and a form of the exponential distribution. Applications are
found in magnetic resonance imaging (MRI) studies. As MRI images are recorded as
complex images but viewed as magnitude images, the Rayleigh distribution is used to
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model background data. Usefule for estimating the noise variance in an MRI image
from background data. Its pdf
f(x|σ) = x
σ2
e
−x2
2σ2 , x ≥ 0 (3.18)
The Rician (or Rice) distribution is a probability distribution of the magnitude
of a circular bivariate normal random variable with potentially non-zero mean. R ∼
Rice(ν, σ) if R =
√
X2 + Y 2 where X ∼ N(νcosθ, σ2) and Y ∼ N(νsinθ, σ2) are
statistically independent normal random variables and θ is any real number. The
Rician distribution is related to the Poisson distribution, Chi-Square distribution,
Rayleigh distribution, exponential distribution. Its pdf
f(x|ν, σ) = x
σ2
exp
(−(x2 + ν2)
2σ2
)
I0
(xν
σ2
)
, ν ≥ 0, σ ≥ 0, I0 is the Bessel function.
(3.19)
The t-Location Scale distribution is a non-standardized Student’s t-distribution
where σ does not correspond to a standard deviation. It is not the standard de-
viation of the scaled distribution nor standard deviation of the underlying normal
distribution, it is simply the overall scale of the distribution. Useful in Bayesian In-
ference where the inverse gamma distribution is the conjugate prior distribution of
the variance of a Gaussian distribution. Its pdf
f(x|ν, µ, σ) = Γ
(
ν+1
2
)
Γ
(
ν
2
)√
piνσ
(
1 +
1
ν
(
x− µ
σ
)2)− ν+12
(3.20)
The Weibull distribution, related to both the Exponential distribution and the
Gamma distribution, plays an important role in the analysis of failure time data. Its
pdf
f(x|γ, β) = γ
β
xγ−1e
−xγ
β , 0 ≤ x <∞, γ > 0, β > 0 (3.21)
The list of parametric distributions for fitting original sleep measure data corre-
sponding to discrete variables that were considered consisted of: Binomial, Negative
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Binomial, and Poisson. Following are descriptions and applications of these. The
Binomial distribution is a discrete distribution of the possible number of successful
outcomes in a given number of trials where each has the same probability of success.
Its pmf
p(x|n,p) =
(
n
x
)
px(1− p)n−x; x = 0, 1, 2, 3, ...., n; 0 ≤ p ≤ 1 (3.22)
The Negative Binomial distribution is a discrete distribution similar to the Bi-
nomial distribution with the exception that we count the number of Bernoulli trials
required to get a fixed number of successes before a specified number of failures
(denoted r) occur. It includes the Poisson distribution as a limiting case. Used in
”contagious” discrete events such as modeling tornado outbreaks, the Negative Bi-
nomial can be used to give more accurate models than the Poisson distribution by
allowing the mean and the variance to be different, unlike the Poisson. ”Contagious”
events have positively correlated occurrences causing a larger variance than if the
occurrences were independent, due to a positive covariance term. Its pmf
p(x|r,p) =
(
r + x− 1
x
)
pr(1− p)x, x = 0, 1, ..; 0 ≤ p ≤ 1 (3.23)
The Poisson distribution is a discrete distribution used to model waiting times,
and also used to model spatial distributions such as distribution of bomb hits in an
area or distribution of fish in the lake. Its pmf
p(x|λ) = e
−λλx
x!
, x = 0, 1, ... (3.24)
The best, fitted distribution was chosen based on appropriate goodness of fit
criteria. After the distributions were uniquely determined (see Appendix Figure A1),
a sample of the same size as the original data (N=62 for each group) was generated
for each of the sleep measure variables separately for cases and controls given their
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derived distributions. As a result, we were able to obtain a sample equal in number
of observations but with added information in the form of distributional assumptions
made from probability distribution of the error terms for each sleep measure variable.
3.5 Results From A Simulated Sample
The sleep measures for the individuals deemed cases were sampled according to
best fitting parametric distribution based on AIC criterion first, before considering
the other goodness of fit criteria.
The apnea and hypopnea index (AHI) was distributed Generalized Pareto(µlocation =
−0.34, σscale = 40.45, ξshape = 6.0).
The total sleep time (TST) was distributed Generalized Extreme V alue(µlocation =
300.94, σscale = 55.10, ξshape = 1.0).
The sleep efficiency was distributed Negative Binomial(r = 18.14, p = 0.20).
The sleep onset was distributed Exponential(β = 22.02).
The rem onset was distributed Rayleigh(σ = 112.63).
The total sleep time in REM stage was distributed Negative Binomial(r = 1.44, p =
0.11).
The arousal index was distributed Generalized Pareto(µlocation = −0.46, σscale =
29.64, ξshape = 3.0).
The stage I sleep measure was distributed Negative Binomial(r = 2.98, p = 0.09).
The stage II sleep measure was distributed Negative Binomial(r = 5.95, p = 0.09).
The stage III sleep measure was distributed Negative Binomial(r = 0.05, p = 0.06).
Age was distributed Logistic(µ = 67.16, β = 5.35).
The sleep measures for the individuals deemed controls were sampled according
to best fitting parametric distribution based on AIC criterion first, before considering
the other goodness of fit criteria.
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The apnea and hypopnea index (AHI) for this group was distributed
Generalized Pareto(µlocation = −0.26, σscale = 32.97, ξshape = 5.1).
The total sleep time (TST) for this group was distributed
Generalized Extreme V alue(µlocation = 313.68, σscale = 48.53, ξshape = 1.0).
The sleep efficiency for this group was distributed Negative Binomial(r = 21.38, p =
0.21).
The sleep onset for this group was distributed Exponential(β = 27.85).
The rem onset for this group was distributed Log − Logistic(α = 4.65, β = 0.33).
The total sleep time in REM stage for this group was distributed
Negative Binomial(r = 2.43, p = 0.15).
The arousal index for this group was distributed Lognormal(µ = 2.54, σ = 0.87).
The stage I sleep measure for this group was distributed Negative Binomial(r =
3.93, p = 0.15).
The stage II sleep measure for this group was distributed Negative Binomial(r =
12.53, p = 0.17).
The stage III sleep measure for this group was distributed Negative Binomial(r =
0.12, p = 0.07).
Age for this group was distributed Logistic(µ = 59.89, β = 5.88).
With a same sized sample (N=62 for cases and N=62 for controls) obtained that
now provide more information about the distribution of each of the variables, differ-
ences between the two groups using a two-sample t-test were again tested. Results
are shown in Table 3.2.
While we see that stage I is still statistically significant (p=0.01), we are also
able to detect other significant differences that might otherwise been undetectable
due to under powered data. Using this new approach of adding more information
via distributional assumptions, significant differences were also found for time spent
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sleeping in REM stage (p=0.04) and sleep efficiency (p=0.01). Our analyses show
that patients with OSA and BPH have low sleep efficiency, decreased time spent
sleeping in REM stage, and spent more time sleeping in light stage (stage I). Although
not statistically significant, analyses also show that patients with OSA and BPH
demonstrate higher AHI.
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3.6 Results From The Simulated Sample After Adjusting for Age
Our analyses also took into account testing and eliminating confounding informa-
tion. Significant differences between the two groups were tested in the original sample
while adjusting for age (Table 3.3) and also in sample with added distributional in-
formation (Table 3.4).
Results demonstrate that in the original dataset (Table 3.3), age is a confounder
and significant associations found tend to go away with adjustment for age. In the
sample generated from a variable’s own parametric distribution (Table 3.4), the sig-
nificant associations found still remain even after the age adjustment. An additional
variable, sleep onset, was also found to be significant after adjusting for age.
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3.6.1 Bootstrapping Results From Many Random Samples
In order to address whether the associations seen in Table 3.4 were simply by
chance or if there was valuable, additional information being added that was given rise
to significant difference not otherwise seen, 5000 samples were drawn each of size 62 for
cases and 62 for controls in where the specified distribution was considered for each.
From Table 3.4 we are able to see whether there are significant differences between
those that are controls and those that are cases on measures of central tendency. This
is also an analogue for determining the odds that a participant will be a case(Y = 1)
or control(Y = 0) given their measure on each of the variables separately. To address
this question, a simple logistic regression model of the following form is be used:
Logit Y = α + βX, for Y = 0, 1 (3.25)
What I am proposing when I sample each of the variables form specific distribu-
tions is that this method adds information. If it adds information, then running the
logistic regression at each iteration would produce a different α and a different β:
Logit Y = α? + β?X, for Y = 0, 1 (3.26)
To determine this information, I sampled 5000 times each time obtaining 62 cases
and drawing random samples for each of the variables with specific distributions
62 controls and drawing random samples for each of these variables with specific
distributions. A confidence interval was obtained for both α? and β? for the variables
that showed a significant difference, and this was compared to the confidence interval
for the same variables in the original raw data. Results are displayed below (Table
3.5).
Table 3.5 shows that the confidence interval for each of the parameters in where
we assumed specific distributions for each of the variables is tighter with a smaller
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Parameter Comparison for Simulated Data Assuming Specific Distributions and Original
Raw Data
Orginal Raw Data Simulated
Data
Sleep Efficiency
β SE 95%CI SE 95%CI
-0.01904 0.01079 (-0.04019, 0.00209) 0.00014 (-0.04093, -0.00067)
α SE 95%CI SE 95%CI
1.41106 0.82213 (-0.200310, 3.02243) 0.01073 (0.07846, 3.03352)
Sleep Onset
β SE 95%CI SE 95%CI
-0.00670 0.00627 (-0.01899, 0.00558) 0.00011 (0.01821, 0.01426)
α SE 95%CI SE 95%CI
0.16564 0.23619 (-0.29730, 0.62859) 0.00280 (-0.32413, 0.44741)
TSS in REM
β SE 95%CI SE 95%CI
-0.03608 0.02280 (-0.08077, 0.00860) 0.00030 (-0.08340, 0.00255)
α SE 95%CI SE 95%CI
0.44979 0.33641 (-0.20956, 1.10916) 0.00368 (0.01765, 1.04012)
Stage I
β SE 95%CI SE 95%CI
0.02597 0.1268 (-0.22255, 0.27449) 0.00019 (-0.01057, 0.04302)
α SE 95%CI SE 95%CI
-0.61949 0.34541 (-1.29650, 0.05750) 0.00471 (-1.03154, 0.25789)
Table 3.5: Parameter Comparison for Simulated Data Assuming Specific Distribu-
tions and Original Raw Data
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Figure 3.1: Estimation of the Mean of Beta and Alpha for Each of the Variables
standard error, in comparison to the parameter confidence intervals derived from the
original raw data. In each of the figures attached, β and α do converge in the sense
that the variability displayed stays within plus or minus 2. The proposed method
adds more information in terms of precision and in turn allows us to find associations
that were otherwise null.
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3.7 Fractional Polynomials
Our outcome variable defined as whether an individual with OSA has BPH or
not, is found to be related to various continuous sleep measure variables in the boot-
strapped data using parametric distributional assumptions. Particularly, sleep ef-
ficiency, sleep onset, time spent sleeping in REM stage, and time spent sleeping
in stage I were all significantly associated with the outcome variable. The natu-
ral starting point is to assume that the influence the independent sleep measures
have on the outcome variable is monotonic; that the straight line model of the form
b0 + b1x will suffice. However, not all the time will the relationship be monotonic.
We propose investigating other models for possible improvements in fit by consider-
ing non-linearity. Splines is another way to handle non-linearity, however the results
are often difficult to interpret given complicated equations at times. Here we fit a
second-order fractional polynomial to the data which are easier to understand and
tackles the non-linearity problem if it exists. In modeling a fractional polynomial,
Royston and Sauerbrei (2008) recommend that a fractional polynomial of degree m
for X with powers p1, p2, ...., pm is given by
φm(X; ξ, p) = ξ0 +
m∑
j=1
ξjX
(pj) (3.27)
where m is a positive integer , p = (p1, p2, ...., pm) is a real-valued vector of powers
with p1 < p2 < .... < pm and ξ = (ξ0, ξ1, ...., ξm) are real-valued coefficients. The
Box-Tidwell transformation is specified by the round bracket,
X(pj) =

Xpj if pj 6= 0,
ln X if pj = 0
(3.28)
In the cases of equal powers, the above formula may be extended, according to
Royston and Altman (1994), for example for m > 1 and pi = pj for at least one pair
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of distinct indices (i, j), 1 ≤ i, j ≤ m. For m = 2, (i, j) = (1, 2) and p = (p1, p2), we
have
φ2(X; ξ, p) = ξ0 + (ξ1 + ξ2)X
(p1), (3.29)
a fractional polynomial of degree 1, not 2. However, the limit as p2 tends to p1 of
ξ0 + ξ1X
(p1) + ξ2X
(p1)
(X(p2−p1) − 1)
(p2 − p1) (3.30)
Royston and Altman proved it is equal to
ξ0 + ξ1X
(p1) + ξ2X
(p1)ln X, (3.31)
a three parameter family of curves.
For m > 2 and p1 = p2 = .... = pm, the previous expression generalizes to
ξ0 + ξ1X
(p1) +
m∑
j=2
ξjX
(p1)(ln X)j−1. (3.32)
For arbitrary powers p1 ≤ p2 ≤ .... ≤ pm, H0(X) is set to 1, p0 = 0 and this extends
to
φm(X; ξ, p) =
m∑
j=0
ξjHj(X), (3.33)
where for j = 1, ...,m
Hj(X) =

X(pj) if pj 6= pj−1,
Hj−1(X)ln X if pj = pj−1
(3.34)
For example, if 5 is the degree of the fractional polynomial and the powers consist
of φ5(X; 0, 1, 2, 2, 2) then the component functions are H0 = 1, H1 = ln X, H2 = X,
H3 = X
2, H4 = X
2ln X and H5 = X
2(ln X)2. In the case of non-positive values of
X, a preliminary transformation of X to ensure positivity is needed.
The assumption is that all models will be fit by maximum likelihood. For given m,
the best power vector p˜ = (p˜1, ...., p˜m) is associated with the model with the highest
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likelihood or equivalently lowest deviance, D. Recall that D(x) = −2 log f(y|x)
For convenience, we use the deviance D(1, 1) associated with the straight line model
φ1(X; 1) (i.e. m = 1, p = 1) as a baseline for reporting the deviances of other models.
The gain G for a model on a given dataset is then the deviance for φ1(X; 1) minus
that for the model in question,
G = G(m, p) = D(1, 1)−D(m, p) (3.35)
Here it is important to note that since G moves in the opposite direction to D, a larger
gain indicates a better fit. Recall that high values of D(x) indicate low values of the
log likelihood and that the data deviates substantially from the model’s assumptions.
When looking at the deviance difference or gain, if this gain is high then it means
D(1, 1) fit of straight line deviates by a lot from the model’s assumptions.
3.8 Application to Logistic Regression Modeling for Predicting OSA w/BPH
versus OSA
The simulated data (adjusted for age) based on each sleep measures unique para-
metric distribution as determined by the probability distribution of the errors will
be used here to determine if linear representations of each of the variables result in
the best fit or if non-linear representations via fractional polynomials are the best fit.
Recall that the dataset comprises of N1 = 62 individuals with OSA and BPH and
N2 with just OSA. Our outcome variable defined as whether an individual with OSA
has BPH or not, is found to be related to various continuous sleep measure variables;
particularly, sleep efficiency, sleep onset, time spent sleeping in REM stage, and time
spent sleeping in stage I were all significantly associated with the outcome variable.
In Table 3.5, we investigate whether fractional polynomials improves the fit.
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Table 3.6 shows the Deviances for various fractional polynomial models with m ≤
2. For the sleep efficiency variable, the best model with m = 1 has p˜ = 3 and
deviance of 152.76. The best model with m = 2 has p˜ = (−2, 1) and deviance of
150.87. Between the two degrees (m = 1 or m = 2), the best model seems to be the
one with the lowest deviance, or the model with m = 2. However, the variable was
not significant when its fractional polynomial form p˜ = (−2, 1) was put in the model
for predicting OSA w/BPH vs OSA; this shows that the best functional form for sleep
efficiency in predicting OSA w/BPH vs OSA is linearly. For the sleep onset variable,
the best model with m = 1 has p˜ = 0 and deviance of 152.44. The best model with
m = 2 has p˜ = (1, 1) and deviance of 151.70. Between the two degrees (m = 1 or
m = 2), the best model seems to be the one with the lowest deviance, or the model
with m = 2. However, the variable was not significant when its fractional polynomial
form p˜ = (1, 1) was put in the model for predicting OSA w/BPH vs OSA; this shows
that the best functional form for sleep onset in predicting OSA w/BPH vs OSA is
linearly. For the time spent sleeping in REM stage variable, the best model with
m = 1 has p˜ = 0.5 and deviance of 169.08. The best model with m = 2 has p˜ = (0, 3)
and deviance of 169.04. Between the two degrees (m = 1 or m = 2), the best model
seems to be the one with the lowest deviance, or the model with m = 2. However, the
variable was not significant when its fractional polynomial form p˜ = (0, 3) was put in
the model for predicting OSA w/BPH vs OSA; this shows that the best functional
form for time spent sleeping in REM stage in predicting OSA w/BPH vs OSA is
linearly. For the time spent sleeping in stage I variable, the best model with m = 1
has p˜ = 0.5 and deviance of 151.55. The best model with m = 2 has p˜ = (−1,−.5)
and deviance of 149.58. Between the two degrees (m = 1 or m = 2), the best model
seems to be the one with the lowest deviance, or the model with m = 2. When put
in the model with its functional form p˜ = (−1,−.5), this variable was significant for
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predicting OSA w/BPH vs OSA. This shows that the best functional form for time
spent sleeping in stage I in predicting OSA w/BPH vs OSA is non-linearly or of the
form stageI−1 + stageI−.5 (p − values = 0.06, 0.04). Note here that significance is
only for stageI−.5 in predicting OSA w/BPH vs OSA.
Our study shows that when data is under-powered, we might be able to find un-
derlying associations by adding distributional assumptions from each variable’s prob-
ability distribution of the error terms. Taking it a step further and using a technique
developed by Royston and Altman, we propose that when we find the underlying asso-
ciations via sampling from each variable’s unique parametric distribution, we are also
able to determine whether this association is best represented linearly or non-linearly.
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3.9 Results and Discussion
This study shows that patients with OSA and BPH demonstrate a decrease in
total sleep time, low sleep efficiency, delayed sleep onset, less REM sleep, and higher
number of arousals. They also show higher Apnea-Hypopnea Index (AHI) and more
time spent sleeping in stage I. We could not find any study documenting sleep archi-
tecture in patients with BPH and OSA. Other published articles show similar findings
of poor sleep in patients with nocturia [3]. A higher proportion of light stage I sleep
in subjects with BPH most likely affects sleep continuity owing to nocturia causing
interruption in sleep which understandably causes delayed REM sleep and shorter
REM sleep. It also suggests that older subjects with BPH may suffer from higher
degree of OSA. Our study suggests subjects with BPH and OSA tend to show higher
AHI. Chou et. al., also found interesting association between OSA and BPH in Tai-
wanese population [11]. While the mechanism for this finding is unknown, it could
be related to androgens as Huggins et. al., showed the essential role of androgens
in prostate pathology. They showed that castration was an effective treatment for
metastatic prostate cancer, a discovery for which Huggins shared a Nobel Prize with
Peyton Rous in 1966 [12]. Many clinical reports suggest that testosterone supple-
mentation in hypoglonadal men is associated with induction or worsening of OSA
symptoms [13, 14]. It could also be from less continuity of sleep owing to higher num-
ber of arousals resulting in less stable upper airway resulting in more deranged lung
mechanics leading to higher flow limitation and higher AHI. Younes et. al., showed
that occurrence of unnecessary arousals at the time of opening airway accentuates
the ventilatory overshoot, further destabilizing breathing [15, 16, 17] which increases
risk for OSA. Our analysis have given new insights on predictors for severity of sleep
apnea and have also generated some interesting questions worth exploring: (1) since
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BPH causes a decrease in sleep efficiency, could this be the cause of poor compliance
with CPAP in patients with OSA and BPH since patients are still suffering form
less efficient sleep despite optimal treatment for OSA? (2) Would treatment of BPH
increase compliance with CPAP? (3) Would treatment of BPH have an effect on OSA
severity or compliance to CPAP treatment for OSA? (4)Could successful treatment
of sleep apnea by CPAP improve BPH symptoms owing to improvement in sleep
architecture? Nonetheless, as a starting point to all of these questions, this study ob-
jectively documents the effect of BPH on sleep architecture in patients with OSA. In
summary, we found that average time spent sleeping in stage I is significantly different
in those with only OSA and those with OSA with BPH in the original unadjusted for
age sample, but the effect of BPH on sleep architecture appears to be blunted by an
under-powered study. Additionally, our findings and proposed methods give rise to
important clinical implications that might otherwise go undetected in light of a low
sample size. With the high costs of conducting a clinical trial with enough patients to
guarantee a power level of at least 80%, our methods propose to achieve finding as-
sociations that might otherwise go undetected by providing more information about
each variables probability distribution from its error terms, without the burden of
high costs. Once this information is obtain via parametric assumptions, our goal is
then to determine whether the associations found should be linear or non-linear.
As with any quantitative modeling study, our study has some limitations and
its results are applicable under its assumptions. First, the cross-sectional design did
not allow us to examine causal relationships. Second, our results may not general-
ize to studies in where participants might not represent independent and identical
quantities. We have carried out simple validation of our approach by comparison of
results from other well known statistical methods; however, results could get further
strengthened via a larger validation through patient data having a higher sample size.
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Third, lack of data regarding stages and severity of BPH preclude any observation
regarding severity of BPH with severity of sleep disruption. Likewise data details of
surgical and medical treatment could allow assessment of effect of BPH treatment on
sleep architecture. Nonetheless, this study systematically evaluates the effect of BPH
on sleep architecture in patients with OSA.
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Chapter 4
THE INFLUENCE OF UNDER-REPORTING ON IDENTIFYING RISK
FACTORS FOR KALA-AZAR IN BIHAR, INDIA
4.1 Introduction
Leishmaniasis is a vector-borne disease caused by a protozoan parasite and trans-
mitted by the bite of certain species of sandfly (referred to as “vector”). Leishmaniasis
is endemic in many tropical and sub-tropical countries. Because of the variation in
type of host (animals and/or humans), species of sandfly and parasite as well as
regional differences, the disease is found in many forms, collectively referred to as
“family of diseases”. The most serious and potentially fatal, if left untreated, form of
Leishmaniasis is the “Visceral” form. The Indian state of Bihar is one of the major
foci of Visceral Leishmaniasis (VL) in the world. More than 30% of the worldwide
VL cases are reported from Bihar. Poverty, overcrowding, malnutrition, polygamy,
illiteracy, and poor domestic conditions facilitate the growth of this disease, which is
a major public health problem in India [58].
The Health Information System (HIS) is a key component for any disease con-
trol program, and its accuracy is necessary for the assessment of actual disease bur-
den. Unfortunately in India, Kala-azar surveillance is weak because of partial active
surveillance and absence of public-private partnership for the disease containment in
the affected areas. The surveillance data received to the National Agency (NVBDCP)
by means of monthly, quarterly and annual reports, runs from the more peripheral
facilities to the National level, through the districts and state health structures. The
quality control of routinely collected data is performed by the staff of the National
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and Provincial health structures. However, no formal assessment of data quality and
its transmission has been carried out. Weak surveillance system and irregular active
surveillance for Kala-azar leads to serious under-reporting of VL cases.
More recent pre- and post-intervention studies for 2009 and 2010, have shown that
early VL detection have been accomplished via active case detection strategies which
also reduce delays to diagnosis and treatment [41]. “In 2009 (pre-intervention phase),
VL patients were identified thru active case detection strategies by researchers. Four
active case detection strategies(camp approach, index case approach - focal house
search around known VL case, incentive approach, and blanket approach –house
to house search) were assessed for yield of new VL cases by researchers” [60]. In
2010, Kala-azar Elimination Program (KAEP) staff were trained in these strategies
and in VL case management according to national guidelines accompanied by an
increased procurement of diagnostics and drugs through the national program. It is
believed that “early diagnosis is now feasible with the increasing use of field-based
rapid diagnostic tests (rK39) to detect antibodies to recombinant antigen rK39 which
are highly sensitive (range 98% - 99%) and specific (range 96% - 97%)” [65]. Amidst
these advances, approximately one-third of physicians (especially in the private sector)
in India still rely on tests other than rK39 (despite availability) for VL diagnosis [41].
This continues to pose an under-reporting problem despite the advances via active
case detection strategies.
Previous research on diseases similar to Leishmaniasis has also shown how local
climate variables such as rainfall and temperature can affect the incidence rate of the
disease [45, 48]. These variables can be useful in predicting when outbreaks are at a
higher risk of occurring. However, it is also important to consider the geographical
difference in socio-economic variables such as literacy rates, types of houses, and
distribution of individuals in different working environments, among others, because
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VL is a disease that is heavily associated with third world countries [66].
The goal of this work is to identify risk factors that are significant in predicting
the true burden of Kala-azar in Bihar, which involves first estimating the true disease
burden in Bihar, to help inform mathematical modeling frameworks used to under-
stand the nonlinear dynamics of Leishmaniasis. The process was carried out in two
steps. The first step was to estimate underreporting levels in Bihar using reported
incidence and mortality data from 2003 to 2005, and was achieved by fitting a dy-
namical mathematical model to the temporal reported incidence and mortality data
via a Bayesian parameter estimation procedure. The second step was carried out by
analyzing series of multivariate regression models on various datasets that included
socio-economic and climate factors and the true incidence and true mortality. That
is, the mathematical model captures the spread of Kala-azar in Bihar and estimates
underreporting levels to compute adjusted incidence rates, and suggest mechanisms
responsible for its control. Adjusted (for underreporting) and reported data are then
used via statistical models to explore the relationships between socio-economic and
climate variables, and incidence rates from 2003 to 2005.
In this analysis using data from years 2003 - 2005, we found younger age to be one
of the most significant and consistent predictors of VL incidence and mortality at a
high rate. Equivalently, even with active case detection strategies being developed in
more recent years, VL patients continue to be significantly younger [41]. This adds
validity to methods proposed in this paper for identifying the risk factors that truly
predict the burden of Kala-azar in Bihar to this day. The third step was carried out
by using age as a significant factor and developing an age structured model to not
only study the Leishmaniasis dynamics but also to study the dynamic within each
age compartment.
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4.2 Data Collection and Preparation
We use cases and mortality data from 2003 to 2005 to study the dynamics of VL
and evaluate the effects of the existing control program in Bihar during this time.
The data obtained from Bihar State Health Society via Rajendra Memorial Institute
of Medical Sciences contains monthly reported incidence rates (cases/deaths reported
from government health institutions) (see Table 4.1).
Incidence rate per 1
million individuals a
VL mortality rate
per 1000 infected b
2003 2004 2005 2003 2004 2005
Mean 13.47 16.67 21.64 13.42 6.42 5.28
Median 13.71 16.19 22.56 13.49 6.87 4.48
Variance 12.52 61.70 42.90 41.97 7.88 6.82
1st quartile 11.88 9.85 16.28 7.18 3.93 3.46
3rd quartile 15.72 23.41 25.58 18.02 8.24 6.51
Table 4.1: Visceral Leishmaniasis Reported Data from Indian State of Bihar from
2003-2005.
aThe rate is computed by dividing number of new cases reported in a particular month by the population of Bihar
and then multiplying the resultant number by 1 million.
bThe rate is computed by dividing number of deaths reported in a particular month by the number of new infections
in that month and then multiplying the resultant number by 1000.
The State Health Society of Bihar is divided into 38 District Health Societies
(DHS) which are further divided into Primary Health Centers (PHCs). The health
systems vary substantially. The district hospitals and government medical colleges
are the sources of the reported cases and reported deaths to the DHS. This, therefore,
does not reflect the number of cases reported in privately owned health care facilities.
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It is believed that more than 75% of the VL infected individuals will preferentially
consult private practitioners or one of the not-for-profit private clinics [64]. Because
private health providers are not part of the state public health surveillance system
and continue to have limited knowledge on the innovative tools being developed for
VL care, proper reporting is not undertaken [51]. Thus, the magnitude of the problem
is difficult to assess.
Data from all 33 districts are obtained; however, because VL has been consistently
shown in 21 districts which have high prevalence, the focus in this study is on the
21 districts. Additionally, socio-economic data are also collected. The data represent
literacy rates, education level, worker types, house types, number of medical facilities,
bus services, population density, and are taken from 2001 Census of India, through
the Bihar state government website[43]. Rainfall related data are collected from a
statistical survey carried out by the Directorate of Statistics and Evaluation, Patna,
Bihar [43]. This data included district-wise annual numbers for the variables. These
variables were especially considered due to their high association with third world
living conditions and VL. Education levels were important factors to consider as
better-educated individuals not only provide VL prevention benefits for themselves
through greater disease awareness but can also lead their family and the group(s) for
the uplifting of the community they live in [58]. Types of working population were
also important to consider. Industrial environments may lead to close contacts among
individuals for longer periods of time. Higher movements of marginal workers who
may be infected can enhance the spread of the disease, whereas working in farm lands
might lead to higher exposure of individuals to sandflies, as plants and trees serve as
resting areas for the VL disease vector [58]. Data categorized into types of housing
are also considered as housing conditions have been shown to have significant impact
on disease trends [40]. Climate variables were also important to consider as climate
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variables have long been linked to vector-borne diseases because of the evidence that
the right humidity and temperature can drastically increase the number of sandflies,
and thus incidence of VL [45, 48].
There are 35 factors/variables in the Bihar district data which could be used as
predictor variables. Before any of the statistical or mathematical models are imple-
mented, the raw data is prepared to facilitate further analysis. Because this analysis
heavily relied on derived data, some variables of interest can not be measured directly
but have to be calculated from other measured variables or from literature reviews.
Some examples of derived data used in this study are incidence rates per million popu-
lation and mortality rates per thousand individuals. However, before calculations for
derived data are executed, the absence of some of the data is dealt with appropriately
as follows.
Different sources of data are used and in the absence of detailed datasets, we apply
2 simple methods for estimating missing values: (1) least squares linear regression
method or (2) mean substitution. In the least squares linear regression approach, the
value of the dependent variable Y is predicted based on the value of an independent
variable X. In this study, we have monthly reported data for cases and deaths for each
of the 21 districts for each year from 2003 to 2005. If a particular month is missing
data, using reported data from the remaining years for that same month we use least
squares linear regression to predict the missing cases/deaths. As a result,missing
values are dealt with via a higher-order polynomial used to fit the available data
each time. The obtained polynomial is then used to obtain the missing value each
time. If the fitted high-order polynomial predicts a negative value for either cases or
deaths, then the mean substitution method is used instead. The mean of reported
cases (deaths) for the same month from remaining years replaces the missing value.
The districts for which not all socio-economic or climatic data were not found
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were not considered in the study. This data was only obtained for one year for each
district. Our hope is that the socio-economic factors will capture well the health
disparities seen in Bihar, one of the most illiterate and poor states of India.
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4.3 Infection Dynamics Model to Capture Underreporting Parameter
We use a mathematical model (see Appendix D) that captures transmission dy-
namics and under-reporting levels of VL in a district. The same model framework is
used for each district to estimate district specific incidence under-reporting, however,
parameter estimates were different in each case. The model captures two interacting
populations: humans and vector (sandfly) populations. The human population is
divided into susceptibles (S), infected (I), under treatment (G or T) and permanently
recovered (R) sub-populations. It incorporates the possibility that infected individ-
uals seek treatment at private (T ) or public (G) health facilities. The treatment of
individuals at private health facilities results in underreporting of cases in the state
as private practitioners are not required by law to report cases. Underreporting lev-
els in incidence is captured by parameter(1 − p) and are unknown. The estimates
of transmission coefficients (λh and λv in the Model) are also unknown for VL in
Bihar. Even though we consider a systematic sub-representation of λh = CBhv and
λv = CBvh, we do not estimate their sub-representation parameters. That is, we
estimate transmission coefficients λh and λv as a lumped composite parameters and
not estimate explicitly C, βhv, and βvh separately.
Susceptible humans can be infected with the VL strain following contact with
infected sandflies at an average rate Fh = mCBhv
Z
Nh
S, where m is per-capita average
number of sandflies (assumed constant), C is the average biting rate of a sandfly
on humans in a unit time, and Bhv is the transmission probability of the parasite
given a bite. Susceptible sandflies are infected with leishmania following contact with
infected humans at an average rate Fv = CBvh
I
Nh
X, where Bvh is the transmission
probability of the parasite from an infected human to a susceptible sandfly given a
bite. (See Appendix D).
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4.4 Underreporting
4.4.1 Estimation Method
A Bayesian parameter estimation approach is used to estimate the underreporting
parameter (1 − p) of the mathematical model (see Appendix B) to obtain estimates
of adjusted incidence and mortality rates. We utilize the Metropolis-Hastings Monte
Carlo Markov Chain (M-H MCMC) to fit the model to the observed data from Bihar.
The M-H MCMC algorithm construct Markov Chain, which has limiting invariant
distribution, as follows.
1. Choose initial values of parameters-set X0 (in our case, initial guess were given in
Table 4.4).
2. Choose a candidate estimate value from the proposal distribution conditional on initial
set, i.e., given Xn, generate a candidate Zn+1 from proposal distribution P (Xn, .) (i.e.,
from P (.|Xn)). Perform acceptance criteria on the candidate, i.e., flip an independent
coin, whose probability of heads equals α(Xn, Zn+1), where
α(x, z) = min[1, pratio] = min
[
1,
pi(z) · P (z, x)
pi(x) · P (x, z)
]
= (more precisely) min
[
1,
pi(z) · P (x|z)
pi(x) · P (z|x)
]
where pi(.) is the distribution of the limiting invariant state (initially unknown) of the
chain. If the coin is heads, “accept” the proposal by setting Xn+1 = Zn+1; if the coin
is tails then “reject” the proposal by setting Xn+1 = Xn. (In our case, we considered
symmetric normal distribution as our proposal distribution).
3. Go to step 2 above and repeat. (see Appendix B)
4.5 Statistical Analysis
4.5.1 Multicollinearity of Variables
There were 35 variables in the Bihar district data which could be used as predictor
variables (Tables 4.2 and 4.3). Before using them in a regression analysis it was first
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necessary to test them for independence from each other. First, the variables were
each rescaled to a -1 to 1 range, in order to ensure that magnitude differences in the
variable measures would not impact the results of the co-linearity testing. Rescaling
consisted of standardizing the variables by subtracting the midrange and dividing by
the range for each. Second, the rescaled variables were tested for co-linearity using
variance inflation factors (VIF) and condition indices. The condition indices are the
square roots of the ratio of the largest eigenvalue from design matrix to each individual
eigenvalue. The largest condition index is the condition number of the scaled design
matrix. When this number is small, weak dependencies might be starting to affect
the regression estimates. The VIF provides a measure of how much the variance of
an estimated regression coefficient is increased because of collinearity.
V IFj =
1
1−R2j
(4.1)
where R2j is the coefficient of determination obtained from regressing the jth explana-
tory variable against all other explanatory variables.
If the jth explanatory variable is uncorrelated with all the others then VIF =
1; however, VIF increases as the correlation increases. These factors measure how
much the variances of the estimated regression coefficients are inflated as compared
to when the predictor variables are not linearly related. The general rule of thumb
is that VIFs exceeding 4 warrant further investigation, while VIFs exceeding 10 are
signs of serious multicollinearity requiring correction. In this analysis, the minimum
acceptance value for VIF and the condition indices was 10. All scaled variables were
placed in the model and the variable corresponding to the largest condition index
was removed and the model re-run. This procedure was repeated until a group of
variables meeting the VIF and condition index criterion were identified.
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4.5.2 Best Subsets Algorithm
A best subsets algorithm approach applied to multiple linear regression analysis
was performed to examine relationship between the variables meeting the variance in-
flation factor and the condition index. This approach was performed on both reported
and adjusted (for underreporting) incidence and mortality rates for years 2003-2005.
For these analyses, all ten variables (shown in Table 4.6) were entered as potential
predictors into regression models with the incidence and mortality rates treated as
the dependent measures.
The Akaike Information Criterion (AIC) was used to identify the best subsets
in the algorithm. These algorithms searched for all the subsets of X variables with
the smallest AIC values using much less computational effort than when all possible
subsets are evaluated [44].
Not only do these algorithms provide the best subsets according to the specified
criterion, but they often also identify several good subsets for each possible number
of X variables in the model to give the investigator additional helpful information in
making the final selection of the subset of X variables to be employed in the regres-
sion model. In each case, final linear regression models were selected by minimizing
the AIC, which balances the regression model fit and its complexity. Increasing the
number of parameters in the statistical models improves their fit to the data but at a
cost of increased complexity. Thus, AIC balances the goodness of fit and the number
of included covariates by penalizing the number of parameters in each model consid-
ered. The best model is the one with the lowest AIC. This method is considered more
robust than the traditional stepwise selection procedures and produces parsimonious
models balancing the goodness of fit and model complexity [44].
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4.6 Insight from Statistical Results
By integrating mathematical and statistical models’ analysis, we are able to iden-
tify relevant risk factors for VL in Bihar, India. In this section, we discuss findings
from the Bayesian parameter estimation method, and compare results from the best
statistical models for predicting reported and adjusted incidence, and reported and
adjusted mortality rates as a way to identify risk factors for the VL. Our results also
give insight to the importance of incorporating underreporting. Using age as the
most consistent significant result from the statistical analyses, we proceed to develop
a more precise mathematical model by developing an age structured model to study
dynamics.
4.6.1 Bayesian Estimates from M-H MCMC
Parameter Mean Std. MC error 2.50 % Median 97.50%
δ1 2.395 1.036 0.01784 0.3358 2.514 3.925
δ2 0.501 0.2886 0.004041 0.02702 0.4986 0.9755
η 0.1428 0.08477 0.001472 0.01511 0.136 0.2912
λh 0.792 0.5681 0.01038 0.03014 0.6768 1.918
λv 1.266 0.8699 0.01611 0.04964 1.133 2.899
p 0.188 0.1142 0.002061 0.01525 0.1734 0.3871
Table 4.5: Results from MCMC Bayesian Estimation for the 2004 Data from State
of Bihar
We estimated the 6 parameters (δ1, δ2, η, λh, λv, p) for each of the 21 districts. As
an example, we show results (in Table 4.5) for entire Bihar using 2004 data. The initial
conditions were fixed according to the region of consideration; for example, for the
whole state of Bihar the fixed initial conditions were (S(0)/N = 0.7, I(0)/N = 0.02,
G(0)/N = 0.5E − 3, T (0)/N = 1.5E − 3 and R(0)/N = 0.278). The incidence-
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underreporting level is computed by (1− p) ∗ 100%.
Using the MH-MCMC Bayesian method, we have estimated the underreporting
proportion and used it to adjust the reported incidence and reported mortality rates.
The estimated districtwise underreporting proportions for the three years are given in
the figure in Appendix E. For example, the underreporting proportion for the whole
state in 2004 is 81.2% with credible interval of (69.7, 92.6), see last result of Table
4.5.
4.6.2 Independent Variables Identified Via Statistical Method
Descriptive statistics for independent variables that met VIF criteria are shown
in Table 4.6. These ten independent variables were inputted in the best subsets algo-
rithm as variables and used to identify the best models for predicting both reported
incidence rates and adjusted incidence rates, and used to identify the best models for
predicting reported mortality rates and adjusted mortality rates. This was done to
identify risk factors for Leishmaniasis.
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4.6.3 Impact on Reported and Adjusted Incidence Rates
Overall, there were several variables that were consistently found to be signifi-
cantly associated with reported incidence rates between 2003 to 2005 (see Appendix
F). Six variables were retained as significant predictors of reported incidence rates for
2003. Reduced incidence rates for 2003 were associated with increases in Pop2001 and
decreases in variables Medicalfac1M , PCTprimary, WTmain, Age5−14 and Growthrate10.
Four variables were retained as significant predictors of incidence rates for 2004. In-
creased incidence rates for 2004 were associated with increases in WTmain, Age5−14,
Medicalfac1M , and PCTltprimary. Increased incidence rates for 2005 were also marginally
associated with WTmain. Overall, WTmain and Age5−14 were found to be consistently
significant with the incidence rates for 2003, 2004, and 2005.
It seems that workers classified as main (WT-main) seem to consistently best
predict incidence rates for the years 2003 to 2005 at an increasing rate. This might
be a direct result from idea that industrial environments may lead to close contacts
among individuals for longer periods of time; thus, those that might be infected can
enhance the spread of disease. This is followed by the percentage of children whose
age ranged from 5 to 14 years (Age-5-14). This age group seems to consistently
significantly predict incidence rates for the years 2003 to 2004 at a very high rate.
In a study done by Mueller, where age distribution of patients with VL in endemic
areas in Ethiopia was analyzed via assessment of young and aged mice during the
course of infection, it was concluded that macrophages from younger mice do not
have an impaired capacity to kill parasites and tend to promote parasite growth
more efficiently [56]. Another published study points to certain types of VL affecting
certain pediatric age groups more than others [52]. Our results seem to support the
high incidence rate among the younger group.
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When the incidence rates were adjusted for underreporting, some results coincided
with results for the reported incidence rates. Similar to the reported incidence rates
for 2003, Growthrate10 was found to be a significant predictor for adjusted incidence
rates in 2003. Increased adjusted incidence rates for 2003 were associated with in-
creases in Growthrate10. Similar to the reported incidence rates for 2004 and 2005,
the age group between 5 and 14 years of age was the only significant predictor of
adjusted incidence rates for 2004 and 2005. Increased adjusted incidence rates for
2004 and 2005 were associated with increases in in Age5−14 for 2004 and 2005.(see
Appendix F)
Results for the incidence rates adjusted for underreporting coincide with results
from the reported incidence rates. Interestingly, the age group between 5 and 14 years
of age was a consistent significant predictor for adjusted incidence rates for 2004 and
2005. There seems to be something about this particular age group that promotes
the VL incidence.
In Table 4.7 we show the difference between results from adjusted and unadjusted
incidence rates. When we do not adjust for underreporting, our statistical models
correlate the incidence with more predictors compared to fewer predictors in the case
of adjusted incidence. We are able to target what best predicts incidence when we
incorporate underreporting. Additionally, the proportion of variability accounted for
by each of the statistical models is higher for the models in which the cases where
adjusted for underreporting. Thus, underreporting needs to be incorporated: other-
wise we will get unreasonable results and implications.
Moreover, the total variability of incidence explained by the predictors for each
model representing the different years is higher 66% of the time when the models
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Reported Results Adjusted Results
I2003 Femal −Malrat
Pop2001
Medicalfac1M
PCTprimary
WTmain
Age5−14
Growthrate10 Growthrate10
I2004 Pop2001
Medicalfac1M
PCTltprimary
WTmain
Age5−14 Age5−14
I2005
WTmain
Age5−14 Age5−14
Table 4.7: Reported vs. Adjusted Incidence Rates Results
are adjusted for under-reporting. Variability for reported incidence in 2004 was 41%
compared to 61% for adjusted incidence in 2004. Variability for reported incidence
in 2005 was 25% compared to 27% for adjusted incidence in 2005. The variability
was not higher for adjusted incidence in 2003. Because this total variation usually
can be made larger by including a larger number of predictor variables, a modified
measure (adjusted R2) was used to adjust for the number of predictor variables in each
model. Even after adjusting for the number of predictor variables in each model, the
variability of incidence explained by the predictors for each model is higher when the
models are adjusted for under-reporting. Variability for reported incidence in 2004
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was 25% compared to 57% for adjusted incidence in 2004. Variability for reported
incidence in 2005 was 17% compared to 23% for adjusted incidence in 2005. The
variability was not higher for adjusted incidence in 2003.
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4.6.4 Impact on Reported Mortality Rates
When analyzing the relation between the reported mortality rates and variables
for each year, the rates for those regions that did not have any reported deaths were
predicted using either regression analysis or mean substitution based on available
data. There was one variable that was consistently found to be significantly associated
with the reported mortality rates between 2003 - 2005 (Appendix G). Decreased
reported mortality rates were associated with increases in Age5−14.
One published study that consisted of “reviewing 546 records of patients younger
than 15 years admitted with the diagnosis of VL at the Instituto de Medicina Inte-
gral Professor Fernando Figueira between May 1996 and June 2006” found that the
presence of fast breathing, jaundice, mucosal bleeding and bacterial infections would
increase the risk of death by 3 to 4-fold. The presence of very low counts of neu-
trophils and platelets would increase the risk of death by 3 and 12-fold respectively
[59].
In Table 4.8 we again show the difference between results from adjusted and
unadjusted mortality rates. When we do not adjust for underreporting, our statistical
models correlate the mortality with the younger age group between 5 to 14 years of
age.
The total variability of mortality explained by the predictors for each model repre-
senting the different years is higher 66% of the time when the models are adjusted for
under-reporting. Variability for reported mortality in 2003 was 41% compared to 44%
for adjusted incidence in 2003. Variability for reported incidence in 2005 was 66%
compared to 67% for adjusted incidence in 2005. The variability was not higher for
adjusted incidence in 2004. Because this total variation usually can be made larger
by including a larger number of predictor variables, a modified measure (adjusted
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Unadjusted Results Adjusted Results
CFR2003
Age5−14 Age5−14
Growthrate10
CFR2004
Age5−14 Age5−14
Femal −Malrat
Growthrate10 Growthrate10
Pop2001
CFR2005
Age5−14 Age5−14
PCTltprimary PCTltprimary
Medicalfac1M Medicalfac1M
Table 4.8: Reported vs. Adjusted Mortality Rate Results
R2) was used to adjust for the number of predictor variables in each model. Even
after adjusting for the number of predictor variables in each model, the variability
of mortality explained by the predictors for each model is higher when the models
are adjusted for under-reporting. Variability for reported mortality in 2003 was 36%
compared to 37% for adjusted incidence in 2003. Variability for reported mortality in
2005 was 52% compared to 53% for adjusted incidence in 2005. The variability was
not higher for adjusted incidence in 2004.
4.7 Motivation for Developing an Age Structured Model
Over the last few decades there has been a dramatic increase in the number of
VL cases in India, due to a complexity of factors involved in the transmission of
the parasite. Several studies have shown that malnutrition, environmental aspects,
78
and social and economic conditions are risk factors for VL. In general, risk factors
may include factors related to hosts involved in life cycles of the parasites and their
environments. However, data on socio-economic, and climatic risk factors for VL
are comparatively scarce, and few studies have investigated the impact of such risk
factors on the disease burden of VL in India. Changes in climate and land use
patterns, economic developments, and increasing risk factors are growing concerns
for public health departments in understanding VL outbreaks especially in developing
countries like India. Moreover, current surveillance systems only capture reporting
through public health institutions, while a significant number of VL patients undergo
treatments at private medical facilities resulting in severe underreporting of cases and
deaths in Bihar at that time. In recent years there has been some improvement in
surveillance systems via the incorporation of some active reporting; however, there
is still a long way to go before actual disease burden can be reported from the field.
These issues may severely hinder the efforts to prevent and control the VL in Bihar.
I used dynamical and statistical models to capture disease burden and to identify
risk factors for KA in predicting incidence and mortality levels in India, respectively.
The dynamical model was used to estimate underreporting levels via the reported
data and Bayesian estimation method. The adjusted (for underreporting) incidences
obtained from the model were taken in statistical models and were used to identify
factors that may predict VL disease burden.
Using limited data from 2003 to 2005, we found that underreporting levels in Bihar
ranges from 70% to 90%. The results from the study also provide some perspectives
into socio-economic factors and their relationship to incidence and mortality of VL.
We found that two particular variables were consistently retained as significant pre-
dictors of VL incidence. WTmain, which represented the percentage of the workers
who were employed in industry or factories, was consistently retained as best pre-
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dictor for the incidence of VL for all reported incidence years for the period 2003 to
2005. This might be a direct result from idea that industrial environments may lead
to close contacts among individuals for longer periods of time; thus, those that might
be infected can enhance the spread of disease. The percentage of children whose age
ranged from 5 to 14 years (Age-5-14) also consistently predicted VL incidence at a
high rate. Younger children experiencing malnutrition and extreme poverty environ-
ments tend to have an impaired immune system that could in these cases impaire their
capacity to kill parasites. This could then promote parasite growth more efficiently
[56]. The age group represented by those less than 14 years of age was also the most
consistent predictor of incidence when incidence was adjusted for underreporting and
of reported and adjusted mortality.
Models developed for policy recommendations and implementation must be quite
different than general math models used. In our case, the problem lies in recommend-
ing a specific age group to be the focus of attention in coping with VL outbreak; as
a result, it is necessary that a model that separates the population into a sufficient
number of age groups is used [69]. Since age structure is a critical risk factor in the
transmission dynamics of Leishmaniasis, we conclude this chapter with a minimal age
structured model and its preliminary analysis in order to highlight the nature of the
modeling and technical challenges tied in to the study and parameter estimation of
age structured models[73, 74, 75]. Our next step involved developing a more precise
mathematical model using this information. An age structured mathematical model
was developed to study the dynamics of Leishmaniasis.
4.8 Age-Structured Epidemic Model
I developed an age-structured epidemic model. A typical Susceptible-Exposed-
Infected-Recovered (SEIR) disease flow is assumed. Careful attention is paid to the
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development of the infection rates as these recruitment rates drive the model. Age
is discretized into age intervals or groups, e.g., infants, children, juveniles, adults,
senior citizens, etc. Mild assumptions on the age-dependent parameters are imposed,
namely that these values remain constant over each age group. By treating age as a
discrete, rather than continuous variable and integrating each of the PDE’s in each
of the resulting age groups, it results in a system of ordinary differential equations.
I locate the equilibrium point corresponding to an absence of infection and linearize
about this point to determine under what conditions a small perturbation, in the
form of the introduction of a small number of infections, will cause an epidemic.
This threshold is determined by using the next generation operator. The goal is
to examine the relative growth rates between the sizes of successive generations of
infected individuals and arriving at the desired threshold [69].
4.8.1 Discrete Age Groups
Using the approach described by Fred Brauer and Carlos Castillo-Chavez, the age
axis was divided into four age groups [0, a1), [a1, a2), [a2, a3), [a3, a4) [71]. All the age
dependent parameters were assumed to be constant in each age group (for example,
µj, j, λj, βj, ωj, and γj). N(t) =
∑n
j=1Nj(t) is the total human population as a
function of time. Sj(t) is the number of susceptible humans in age-group j, Ej(t) is
the number of asymptomatic humans in age-group j, Ij(t) is the number of infected
humans in age-group j, and Rj(t) is the number of recovered humans in age-group j.
Individuals progressing out of age group j − 1 to group j at time t are represented
by ηj. So the “aging” rate from group j is ηj and it was calculated as the mean time
spent in group j as 1/ηj [70]. We also assume that there is a constant inflow of human
hosts Λ. Below a schematic diagram from the system is presented in Figure 2.
We have the following system of ordinary differential equations for the human
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Figure 4.1: Compartmental diagram for the human population
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Figure 4.2: Compartmental diagram for the vector
population once we have discretized the age axis into distinct age-groups.
∂S1
∂t
= Λh − (η1 + µ1)− λ1(t)S1 (4.2)
∂S2
∂t
= η1S1 − (η2 + µ2)S2 − λ2(t)S2 (4.3)
∂S3
∂t
= η2S2 − (η3 + µ3)S3 − λ3(t)S3 (4.4)
∂S4
∂t
= η3S3 − µ4S4 − λ4(t)S4 (4.5)
∂E1
∂t
= λ1(t)S1 − (η1 + µ1 + 1)E1 (4.6)
∂E2
∂t
= λ2(t)S2 − (η2 + µ2 + 2)E2 + η1E1 (4.7)
∂E3
∂t
= λ3(t)S3 − (η3 + µ3 + 3)E3 + η2E2 (4.8)
∂E4
∂t
= λ4(t)S4 − (µ4 + 4)E4 + η3E3 (4.9)
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∂I1
∂t
= 1E1 − η1I1 − (µ1 + ω1)I1 + γ1)I1 (4.10)
∂I2
∂t
= 2E2 − η2I2 − (µ2 + ω2)I2 + γ2)I2 + η1I1 (4.11)
∂I3
∂t
= 3E3 − η3I3 − (µ3 + ω3)I3 + γ3)I3 + η2I2 (4.12)
∂I4
∂t
= 4E4 − (µ4 + ω4)I4 + γ4I4 + η3I3 (4.13)
∂R1
∂t
= γ1I1 − (µ1 + η1)R1 (4.14)
∂R2
∂t
= γ2I2 − (µ2 + η2)R2 + η1R1 (4.15)
∂R3
∂t
= γ3I3 − (µ3 + η3)R3 + η2R2 (4.16)
∂R4
∂t
= γ4I4 − µ4R4 + η3R3 (4.17)
where the last η (η4) will equal 0 because no one will age out of this class.
It is assumed that the vector population will have achieved a constant state for
total population (Nv).
∂Ev
∂t
= λv(t)(Nv − Ev − Iv)− (µv + v)Ev (4.18)
∂Iv
∂t
= vEv − µvIv (4.19)
λi(t) = bβ1
Iv
Nh
(for i = 1, 2, 3, 4) and λv = bβv
∑4
i=1 PiIi
Nh
(where Pi is the average
infectivity level of an Ii) represents per capita transmission rates of a vector and a
human host, respectively.
4.8.2 Analysis of the Age-Structure Model
Parameters Estimates of the Model
For example, using a paper on risk of VL based on age-groups, I was able to calculate
the relative risk of developing VL given the age group by using the Odds Ratio
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information given. For the age group from 0 to 14 years of age, the odds ratio was
1.75, and 1.7 for those greater than 14 years of age. As a result, the relative risk of
developing VL will be proportional to the next age group, where the proportionality
constant can be defined as k = 1.75/1.7 = 1.029 [76].
Infection-Free Equilibrium
I determined the infection-free equilibrium; the steady state corresponding to the
absence of infection in all populations. The goal is to determine the conditions under
which an infection can “invade” a population. In other words, when will the infection
spread by introducing a small number of infected individuals (humans or vectors)
into the population. We can find this by calculating R0, the number of sescondary
infections caused by the first infected in a completely susceptible population. Setting
the equations equal to zero, we find the unique equilibrium point to satisfy Ij = Iv = 0
for all j. We then see that Ej = Rj = Ev = 0. We find that the equilibrium
susceptible states to be:
S01 =
Λh
µ1 + η1
(4.20)
S0j =
ηj−1
µj + ηj
S0j−1 for j = 2, ..n (4.21)
S0v =
Λv
µv
(4.22)
Computation of Reproduction Number via The Next Generation Operator
Method
I treat generations of infections rather than treating time in the usual sense. For ex-
ample, the originally infected individuals are the first generation, those they infect are
the second generation, those that second generation infects are the third generation,
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etc. It describes the evolution of spread of the infection through these generations.
Essentially, the rate of the sizes of the generations will be the threshold condition
that determines the stability of the infection-free equilibrium.
F, the new infection matrix, is of the following form:
0 0 0 0 0 0 0 0 0 f1
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 f2
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 f3
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 f4
0 0 0 0 0 0 0 0 0 0
0 g1 0 g2 0 g3 0 g4 0 0
0 0 0 0 0 0 0 0 0 0

where f1 = bβ1
S1
Nh
, f2 = bβ2
S2
Nh
, f3 = bβ3
S3
Nh
, f4 = bβ4
S4
Nh
, and g1 = bβvP1
Sv
Nh
,
g2 = bβvP2
Sv
Nh
, g3 = bβvP3
Sv
Nh
, g4 = bβvP4
Sv
Nh
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The V matrix is of the following form:
a 0 0 0 0 0 0 0 0 0
b c 0 0 0 0 0 0 0 0
d 0 e 0 0 0 0 0 0 0
0 d f g 0 0 0 0 0 0
0 0 h 0 i 0 0 0 0 0
0 0 0 h j k 0 0 0 0
0 0 0 0 l 0 0 0 0 0
0 0 0 0 0 m n o 0 0
0 0 0 0 0 0 0 0 p 0
0 0 0 0 0 0 0 0 q r

where a = η1 + µ1 + 1, b = −η1, c = η1 + µ1 + ω1 + γ1, d = −η1, e = η2 + µ2 + 2,
f = −2, g = η2+µ2+ω2+γ2, h = −η2, i = η3+µ3+η3, j = −3, k = η3+µ3+ω3+γ3,
l = µ3 + 4 − η3, m = −η3, n = −4, o = µ4 + ω4 + γ4, p = µv + v, q = −v, r = µv
The next generation operator is the matrix FV −1 and the reproduction number
is the spectral radius and defined as: R0 = σ(FV
−1)
It then follows that the R0 when there are no age groups considered is:
R0 =
√(
f1v
µvc1
)(
g11
a1b1
)
Here a1 = a, b1 = c, c1 = p. Note,
f1v
µvc1
(= bβ1
µv
v
(µv+v)
S0
N0h
) represents average num-
ber of new cases in human population generated by one infected vector and g11
a1b1
(= bβvP1
(η+µ+)
1
(η+µ+ω+γ)
S0v
N0h
) represents average number of new cases in vector population
generated by one infected individual. The R0 can be interpreted as a geometric mean
of these two last quantities.
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When there are two age groups, R0 is:
R0 =
√
v(f1g1a2b21 + f1g2a21η1 + f1g2b12η1 + f2g2a1b12)
µvc1b1b2a1a2
When there are three age groups, R0 is:
R0 =
(
f1v
µvc1
[(
g11
b1a1
)
+
(
g21η1
b2a1b1
)
+
(
g2η12
b2a1a2
)
+
(
g31η1η2
b3a1b1b2
)
+
(
g3η12η2
b3a1a2b2
)
+
(
g3η1η23
b3a1a2a3
)]
+
(
f2v
µvc1
)[(
g22
b2a2
)
+
(
g32η2
b3a2b2
)
+
(
g3η23
b3a2a3
)]
+
(
g33
b3a3
)(
f3v
µvc1
))1/2
4.8.3 Results
The analysis of the model suggests existence of two equilibria, namely, disease-free
and endemic equilibria. The results also provide condition on stability of the disease
free equilibrium. Analytical calculations related to the computation of the endemic
equilibrium is difficult, however, numerical simulations suggest its existence and local
stability.
The analytical results can be interpreted as follows:
• If R0 can be reduced below 1, then VL can be controlled. Note, the R0 is a
function of all age-dependent parameters as well as parameters that could be
modified by interventions.
• If R0 > 1 then VL remains endemic and the level of endemicity depends on the
estimate of R0 for the region.
• In VL naive region, introduction of an infected in the region may results in VL
outbreak if R0 > 1.
• Estimates of age-dependent parameters of the model can be used to study sen-
sitivity and variability of VL endemic prevalence as a function of parameters.
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4.9 Conclusions
In this chapter, we provided a procedure to link statistical models with mathemat-
ical models. The link was established via three different steps: (1) A mathematical
model is used to estimate true incidence levels via fitting of the model to the underre-
ported available data and bayesian MCMC statistical approach, (2) Regression-based
statistical models were then developed to identify critical risk factors for the true
incidence levels, and (3) The identified critical factor (age was identified as critical
to the incidence) was finally used in the development of a mathematical model to
understand the transmission dynamic of the Visceral Leishmaniasis in India.
In the third step, I considered age as a discrete variable by subdividing the pop-
ulation into age groups. I use SEIR type compartmental model for the disease flow
in the human population and SEI type model in the vector populations. For n age
groups, we have 4n + 2 nonlinear ordinary differential equations. I used the next
generation operator to derive this threshold condition. Reproduction number (R0)
is the expected number of secondary infections produced by a typically infectious
individual in a wholly susceptible population. In the vector-borne disease case, R0
is a geometric mean of the two components: (1) average number of new infections
in vector population generated by one infected individual and (2) average number of
new infections in human population generated by one infected vector. It could be
interpreted in a similar way as for a typical human disease, where vectors are not
involved, that is, it represents average number of new infections in human (vector)
population generated by one infectious human (vector). I also showed that R0 for our
model is actually the geometric mean of both of these quantities.
This chapter ended with the demands for an age-structured model, the result of
the identification of “age” as the critical risk factor associated with Leishmaniasis’
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transmission. The task of parametrizing such a model in the context of Leishmaniasis
would extend the time needed to complete this dissertation and hence is only carried
out here in a simple sense and will be a part of the future work. Nevertheless, a
minimal age-structured model is introduced to highlight the nature of the mathe-
matical analysis and the challenges that we face in modeling neglected diseases such
as Visceral Leishmaniasis. The challenges associated with parametrizing age struc-
tured models can be seen in similar studies conducted by Shim and also by Sutton
[73, 74, 75]. However, the model used in these studies are applied to common diseases,
which are non vector borne diseases.
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Chapter 5
LIMITATIONS AND FUTURE WORK
5.1 Limitations
The study addressed three primary theoretical modeling-related questions: (1)
how to analyze collected data when sample size is limited, and how modeling as-
sumptions varied results of data analysis. In the second chapter, we showed how to
design, collect, and analyze the relevant data through survey. The data collected
from the survey represented the first national survey of its kind understanding PCA
administration across 48 states. While some of the associations seen in the analysis of
the survey data were expected, by applying statistical methods that only work under
certain assumptions, insights were drawn on the depth of the lack of standardization
between hospitals, the implications of mistakes, and inferences made due to large
number of research hospitals being part of the survey. In the fourth chapter, the
differences in quality of health system and hospitals (public vs private) are evident;
this highlights where the underreporting comes from. This type of underreporting
was not so clear from the survey analyzing hospital practices until statistical analyses
requiring specific assumptions were conducted and the magnitude of underreporting
came to light. In the second chapter, the underreporting took the form of the magni-
tude of lack of standardization seen across different institutions. (2)How to identify
hidden associations and nonlinearity of these associations using such under-powered
data: In the third chapter, the association of men with BPH and OSA is compared
with men that only have BPH on clinical and demographic variables. We expected
certain differences to be seen that only came to light after assuming distributional
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assumptions on the measures. This type of method gave insight into yet another type
of underreporting: lack of information as it pertains to distributional information for
each of the variables. (3)How statistical models provide more reasonable structure to
mathematical modeling framework that can be used in turn to understand dynamics
of the system: In the third chapter, we detect underreporting given the day to day
operations in Bihar, India, estimate the underreporting via statistical methods, use
the estimate to adjust incidence and mortality, and discover that children in between
the ages of 5 and 14 are significant in all statistical models ran. This type of underre-
porting is two-fold: underrporting in terms of disease cases being reported by private
health facilities, and underreporting in the sense that true associations are hidden
due to lack of information being provided by health facilities. This dissertation very
elegantly mixes the uses of statistics and mathematical modeling in order to address
pressing issues by first appropriately dealing with lack of information from different
sources.
5.2 Future Work
My future work will extend the methodology developed in this dissertation to
throughly undertake understanding of transmission dynamics of a neglected disease,
Visceral Leishmaniasis (VL) on the face of limited available data from the region and
elimination goals.
VL is one of the most neglected diseases in the world, affecting the poorest seg-
ments of rural populations, causing significant morbidity and mortality. The cam-
paign to eliminate VL (to reduce the annual incidence to less than one per 10,000 at
the district level) has been underway since 2005 but has been unable to even reach
intermediate targets of reducing burden. The Indian state of Bihar is one of the major
foci of VL in the world. More than 30% of the worldwide VL cases are reported from
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Bihar. Poverty, overcrowding, malnutrition, polygamy, illiteracy, and poor domestic
conditions facilitate growth of this disease, which is a major public health problem
in India. The Health Information System (HIS) continues to be a key component
for any disease control program, and its accuracy is necessary for the assessment of
actual disease burden. Unfortunately in India, Kala-azar surveillance is weak because
of partial active surveillance and absence of public-private partnership for the disease
containment in the affected areas. Different sources of data were used in the absence
of detailed datasets. Monthly incidence and mortality data from the 21 most affected
districts were obtained from Bihar State Health Society via Rajendra Memorial In-
stitute of Medical Sciences, Patna. The additional data included demographic (such
as population density, female to male ratio, age groups, decadal growth rate), social
(such as literacy rates by gender, education level and percentage of home schooled
and percentage with graduate education), and economic (such as worker types, house
types, number of medical facilities, bus services, number of livestock, and number of
poultry) variables and were taken from the 2001 Census of India, through the Bihar
state government website [3]. Climatic data (such as rainfall related variables) was
collected from a statistical survey carried out by the Directorate of Statistics and
Evaluation, Patna, Bihar[3]. In my current research, I developed a novel quantita-
tive technique, which handles the sparse data to estimate true burden, identify its
risk factors, and understand VL transmission dynamics in one of the most vulnerable
population of the region. The true VL burden was estimated using a mathematical
model that used a least squares approach that derived the district-wise underreport-
ing levels from available reported incidence data from Bihar during 2003 to 2005.
The case-underreporting estimate was used to then adjust the incidence and mortal-
ity for under-reporting. After adjusting for under-reporting, biostatistical analysis
was used to find the most significant predictors (risk factors among demographical,
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social and economical variables) of mortality and incidence within this timeframe. In
all of the statistical models developed, a specific age group (children between 5 and
14 years old) showed to be the most significant predictor of incidence and mortality
both adjusted and not adjusted for under-reporting. This led to the idea that age
related disparity may be relevant to understanding the dynamics of the VL in India,
Hence, we developed and analyzed an age structured mathematical dynamic model to
identify which age-related epidemiological quantities are critical to dynamics of VL.
We found infection-susceptibility and disease-related mortality for children less than
14 years are more important parameter as compared to age-dependent incubation
and infectious periods for same and other age-groups. My research objectives are to
extend my current research by additionally collecting recent data (for example, inci-
dence, and mortality from the past three years) so that we can evaluate practicality
of VL elimination target, which is aimed to be achieved by 2020. Rather than collect
data from different sources (Bihar state health society and census) like before, the goal
for this project is to collect not only the same type of variables collected before but
also collect additional information on a couple of new variables such as caste (lowest,
lower, middle, upper classes), and religion (Buddhists, Muslims, Sikhs, Christians,
Hindus), from the same patient data which would account for less variability in the
measures. Using this newer information, I plan to carry out broadly the similar objec-
tives: (1) estimate the underreporting by using Markov Chain Monte Carlo (MCMC)
approach, which will give information in terms of the shape of the parameter’s poste-
rior distribution which is more informative (2) using statistical methods, I then plan
to identify the risk factors (including a couple of new variables) most associated with
incidence and mortality for the newer data, adjusting and not adjusting for underre-
porting, and compare the results and (3) with the aid of conclusion from objective
two, develop a reasonable dynamic mathematical model in order to understand the
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impact of identified risk factors after adjusting for underreporting on the transmission
dynamics of VL in Bihar, India and VL elimination target. In particularly, the sec-
ondary aims of the objective two will be to subset the data by age groups, gender, and
religion and address following sub-questions critical for elimination: (2a) to identify
which disparities and to what level are risk factors driving patient’s symptoms at the
initiation of treatment (thus, the quality of treatment received) (2b) to evaluate the
factors that are delaying certain subset of groups from presenting to hospitals once
they have the disease and (2c) to determine the likelihood of certain groups seeking
a local healer vs professional practitioner given their first VL onset. All of these aims
will be investigated and used collectively to study how these results will impact the
transmission dynamics of VL in Bihar, India via mathematical models. A similar
approach was conducted in a study looking at the epidemiological impact of rotavirus
vaccination programs in the United States and Mexico [72].
Two Sample-Tests or One-Way ANOVA will be used to address Aim1, Aim 2 and
3, and test for univariate associations with both updated incidence and mortality
(both adjusted and not adjusted for underreporting). Multivariate linear regression
analyses will be used based on the results from the univariate analyses; a best subsets
algorithm will be used to determine the best predictors of incidence and mortality for
the more recent years. A logistic regression analysis will be used to address likelihood
of patients to see a professional vs local healer on their first presentation. A random
intercepts and random slopes repeated measures analysis will be used to assess risk
change over time for the different factors considered. Using the results from all of the
Aims, a Susceptible, Exposed, Infected, Recovered (SEIR) model will be developed
to study how this new significant information alters the dynamics of the disease and
its progression in the different age compartments now by gender via an age structure
mathematical model.
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1. What is your position (title)?
2. What is your profession?
3. What is your location (city)?
4. What is your location (state)?
5. Indicate number of beds?
6. Are you teaching?
Yes
No
7. Please indicate whether nurses, respiratory therapists, and pharmacists receive
on-going training in PCA procedure and use?
8. What patient risk factors do you consider for patients initially going on PCA
(please check all that apply):
Obesity
Low Body Weight
Concomitant Medications that Potentiate Sedative Effects of Opiate PCA
Pre-existing Conditions such as Asthma, COPD, Sleep Apnea
Advanced Age
Opioid Naive
9. Patients going on PCA are provided with information on (please check all that
apply):
Proper Patient Use of PCA Pumps
Purpose of Monitoring
10. Before PCA pump initiation, refilling, or programming change, two healthcare
providers double-check (please check all that apply):
Patient’s Identification
Patient Allergies That Appear on Medication Administration Record
Drug Selection and Concentration Confirmed as That Which Has Been Pre-
scribed
Any Necessary Dose Adjustments Completed
PCA Pump Settings
Line attachment to patient and tubing insertion into pump
11. For post-operative patients using PCA, my healthcare facility continuously elec-
tronically monitors (please check answers that apply):
All Patients for Oxygenation with Pulse Oximetry
Only Some Patients for Oxygenation with Pulse Oximetry
All Patients for Ventilation with Capnography
Only Some Patients for Ventilation with Capnography
Do Not Electronically Monitor
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12. For these post-operative patients, please describe the PCA pumps used (please
check all that apply):
All of Our PCA Pumps are Smart Pumps that Contain Safety Software and
Medication Libraries to Avoid IV Infusion Programming Errors
Some of Our PCA Pumps are Smart Pumps that Contain Safety Software
and Medication Libraries to Avoid IV Infusion Programming Errors
All of Our PCA Pumps are Smart Pumps with Integrated End Tidal Moni-
toring
Some of Our PCA Pumps are Smart Pumps with Integrated End Tidal Mon-
itoring
Our PCA Pumps are Not Smart Pumps
13. How Long Have You Been Using PCA Pumps That Contain Safety Software
and Medication Libraries?
10 Years or More
5-10 Years
3-5 Years
1-3 Years
Less Than a Year
Do Not Use Smart PCA Pumps That Contain Safety Software and Medication
Libraries
14. How Would You Describe Your Healthcare Facility’s Experience with Continu-
ous Electronic Monitoring?
Don’t Monitor but are Considering Its Use
Too Early to Determine or Have Not Determined
We Monitor Continuously and We Have Seen Reductions in the Overall Inci-
dence of Adverse Events Related to PCA Use
We Monitor Continuously and I Believe We Have Averted Adverse Events
We Monitor Continuously and We Have Seen a Return on Investment When
Measured Against Costs and Expenses (including litigation costs) that We
Might Have Incurred
15. What Do You Believe Would Help Improve The Ease of Assessing a Patient’s
Condition by Nursing Staff Faced With Interpreting Multiple Vital Sign Moni-
tors? (please check all that apply):
A Single Indicator That Accurately Incorporates Key Vital Signs, such as
Pulse Rate, Sp02, Respiratory Rate, and etC02
More Clinical Training for Caregivers
Recommendations on How Best to Easily Make Such Assessments
16. How Would You Rate Your Concern About Potential Alarm Fatigue About
Continuous Electronic Monitoring? :
Not Concerned At All
Concerned but Don’t Believe It Will Be an Unmanageable Problem
Concerned That It Will Be a Problem That Is Difficult to Manage
Concern is Preventing Us From Implementing
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17. Do You Believe That Reduction of False Alarms Would Increase The Use of
Patient Monitoring Devices, Like an Oximeter or Capnograph? :
Yes
No
18. Please Indicate Whether Your Facility’s Identity and This Information Can Be
Made Public in A Searchable Database Similar to HealthGrades :
Yes
No
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Figure C.1: Patient Risk Factors Considered
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Since human and sandfly populations approach demographic equilibrium after a
sufficiently large time in our analysis, we consider the limiting system at the model
where Nh and Nv are assumed to have reached equilibria. Using results from [62] and
[63], the original system asymptotically approaches the limiting system given by the
following scaled model:
Figure D.1: Transitions for FlowChartLast
Table D.1: Model Variables
Variable Definition
s Proportion of susceptible humans in the population where s = SN
i Proportion of infected humans in the population where i = IN
g Proportion of humans undergoing treatment at public health facilities where g = GN
τ Proportion of humans undergoing treatment at private health facilities where τ = TN
r Proportion of recovered individuals in the population where r = RN
Nh Total population of humans
x Proportion of susceptible vectors where x = XN
z Proportion of infected vectors where z = ZN
Nv Total vector population size
s′(t) =bh − λhs(t)z(t)− µhs(t)
i′(t) =λhs(t)z(t)− (η + µh + δ1)i(t)
g′(t) =pηi(t)− (α1 + µh + δ2)g(t)
τ ′(t) =(1− p)ηi(t)− (α2 + µh + δ2)τ(t)
r′(t) =α1g(t) + α2τ(t)− µhr(t)
x′(t) =bv − λvi(t)x(t)− µvx(t)
z′(t) =λvi(t)x(t)− µvz(t)
(D.1)
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The reproduction number for the Model is
R2c =
(
λv
µh + δ1 + η
)(
λh
µv
)
.
Acceptance Probability Computation
The acceptance probability is computed (using conditional probability formula)
via
pratio =
pi(x(∗)) · P (x(n)|x(∗))
pi(x(n)) · P (x(∗)|x(n)) =
L(y|x(∗)) ·∏Qk=1 Pr(x(∗)k )
L(y|x(n)) ·∏Qk=1 Pr(x(n)k ) (D.2)
where Pr(.) represent prior probabilities.(In our case, uniform priors were assumed
for the estimated parameters). The likelihood is given by
L(y|x) =
T∏
i=1
(
1√
2pi
)
× exp
(
− [ logit(yi)− logit(fi(x)) ]
2
2
)
(D.3)
where yi represent observed data (in our case, it is reported monthly incidence and
mortality rates), and proposal distribution is assumed to be multivariate normal
distribution (a symmetric distribution). Note, conditional probability in equation (2)
is:
P (x(∗)|x(n)) = (2pi)−Q/2det(Σ)−1/2 exp
(
−1
2
(
x(∗) − x(n))T Σ−1 (x(∗) − x(n))) (D.4)
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Figure E.1: Underreporting
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